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Hui Huang 
SYSTEM BIOLOGY MODELING: THE INSIGHTS FOR COMPUTATIONAL DRUG 
DISCOVERY 
Traditional treatment strategy development for diseases involves the identification of 
target proteins related to disease states, and the interference of these proteins with drug 
molecules. Computational drug discovery and virtual screening from thousands of 
chemical compounds have accelerated this process. The thesis presents a 
comprehensive framework of computational drug discovery using system biology 
approaches. The thesis mainly consists of two parts: disease biomarker identification and 
disease treatment discoveries. 
 
The first part of the thesis focuses on the research in biomarker identification for human 
diseases in the post-genomic era with an emphasis in system biology approaches such as 
using the protein interaction networks. There are two major types of biomarkers: 
Diagnostic Biomarker is expected to detect a given type of disease in an individual with 
both high sensitivity and specificity; Predictive Biomarker serves to predict drug 
response before treatment is started. Both are essential before we even start seeking any 
treatment for the patients. In this part, we first studied how the coverage of the disease 
genes, the protein interaction quality, and gene ranking strategies can affect the 
identification of disease genes. Second, we addressed the challenge of constructing a 
central database to collect the system level data such as protein interaction, pathway, etc. 
Finally, we built case studies for biomarker identification for using Diabetes as a case 
study. 
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The second part of the thesis mainly addresses how to find treatments after disease 
identification.  It specifically focuses on computational drug repositioning due to its low 
lost, few translational issues and other benefits. First, we described how to implement 
literature mining approaches to build the disease-protein-drug connectivity map and 
demonstrated its superior performances compared to other existing applications. Second, 
we presented a valuable drug-protein directionality database which filled the research gap 
of lacking alternatives for the experimental CMAP in computational drug discovery field. 
We also extended the correlation based ranking algorithms by including the underlying 
topology among proteins. Finally, we demonstrated how to study drug repositioning 
beyond genomic level and from one dimension to two dimensions with clinical side 
effect as prediction features.    
Huanmei Wu, PhD, Chair 
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Chapter 1. Introduction to Drug Discovery with System Approaches 
The complexity of human biology makes it challenging for drug discovery. 
Traditionally drug discovery involves disease identification for the patients and 
treatment identification for the patients with that specific disease. The former 
corresponds to reliable disease biomarker development for the diagnostic purpose. The 
latter refers to develop effective medicines for the treatment. With the development of 
omics-based techniques, systems biology leverages the high-throughput data to 
connect molecular network and pathway information to build better disease models 
and help predict drug effects in patients. 
1.1 Disease Biomarker Identification 
Biomarkers are molecular signatures that enable early diagnosis, guide molecularly 
targeted therapy and monitor the activity and therapeutic responses across a variety of 
disease. They are increasingly important in both therapeutic and diagnostic processes. 
The hope of finding new biomarkers for assessing cancer risk, detecting cancer at an 
early stage, subtyping tumours, selecting optimal therapies, and monitoring therapeutic 
response is the motivation behind substantial current investments in biomarker research. 
Biomarker can be classified according to its purpose. Diagnostic Biomarker is expected 
to detect and identify a given type of disease in an individual with both high sensitivity 
and specificity. Prognostic Biomarker is used to predict the probable course of the disease 
including it recurrence and progression once the disease status has been set. Predictive 
Biomarker serves to predict drug response before treatment is started. Generally, this 
marker classifies individuals as likely responders or non-responders to a particular 
treatment.  
 
The identification of biomarker involved in human diseases has been a primary focus of 
post-genomic biomedicine for pursuing the clinical goals of diagnosis and therapeutic 
treatment. Recent advances in genomics, transcriptomics, proteomics, and metabolomics 
have begun to help unravel the disease molecular mechanisms. Gene expression profiling 
has revealed common gene fusions and expression ‘signatures’ in cancer patients. For 
example, two studies show that the common recurrent gene fusion between TMPRSS2 
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and ERG promotes prostate cancer in both mouse and humans, when the function of 
PTEN is concurrently lost(1).  
 
From a systems perspective, one of the emerging themes today is to re-characterize a 
protein’s biological function in their molecular interaction network and pathway context. 
Network Biomarker (2-4) is a new concept for biomarker discovery in systems biology. 
By integrating cancer susceptibility genes, gene expressions, and their protein interaction 
network, Marc Vidal’s group at Harvard constructed a protein interaction network for 
breast cancer susceptibility and identified HMMR as a new susceptibility locus for the 
breast cancer (5). Later, Trey Ideker’s group at UCSD integrated protein network and 
gene expression data to improve the prediction of metastasis formation in breast cancer 
patients (4, 6). The two studies suggest that protein interaction networks and pathway, 
although drafty and incomplete, can serve as a molecular-level conceptual roadmap to 
guide cancer biomarkers studies (7). 
 
Pathway Biomarker (8) is a concept for biomarker discovery by integrating functional 
genomics and known signaling pathway data. Recent finding suggests that cancer is 
dysregulated at the pathway level. Coupling Omics results with molecular signaling 
pathways involved in cancer and studying how cancer cellular function is regulated at the 
pathway level have been a key topic in cancer systems biology.  
1.2 Drug Discovery  
Traditional treatment strategy development for diseases involves the identification of 
target proteins related to disease states, and the interference of these proteins with drug 
molecules. An explosion of high-throughput data has help measure the drugs’ effect 
experimentally. For example, the experimental Connectivity Map (15) contains more 
than 7,000 expression profiles representing 1,309 compounds. It enables researches on 
pharmacology at gene expression levels. By correlating the disease gene expression with 
the pharmacology profiling from CMAP, Lamb (15) identified novel drug indications in 
diet-induced obesity or Alzheimer's disease. Other pharmacology databases like 
NCI60(20) and CCLE(21) haven also been developed to provide pharmacological 
profiles about drug sensitivity. 
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Computational drug discovery and virtual screening from thousands of chemical 
compounds have accelerated this process. The conventional “One disease, One gene, 
and One drug” paradigm (9) works effectively for simple genetic disorders. However, 
recent research studies show, in the case of both older psychiatric drugs and modern 
anticancer therapies, that drugs with multiple targets can contribute to the drug’s 
therapeutic efficacy(11). Thus the concept of network pharmacology (12)or network 
medicine (13) has been developed to understand the actions of drugs by considering 
targets in the context of the biological networks. Such a bioinformatics network 
analysis of high-throughput data sets offers an opportunity for integration of biological 
complexity and multilevel connectivity(14). 
 
Machine learning or text mining based methods have been developed to overcome some 
of those limitations. Gottlieb (22) developed a logistic regression method called 
PREDICT to predict drug actions. The regression is mainly based on drug-drug similarity 
(i.e. chemical similarity, side effects, drug targets sequence similarity, PPI and GO 
distance) and disease-disease similarity (i.e. similarity from text mining and human 
phenotype ontology). The PREDICT achieves an AUC of 0.9 while the AUC of above 
mentioned CMAP method is only around 0.4. Another approach called The 
Connectivity Maps (C-Maps) web server (23) is an online bioinformatics resource that 
provides biologists with potential relationships between drugs and genes/proteins in 
specific disease contexts based on network mining and literature mining. Disease-
specific protein-drug association profiles are computationally generated by mining bio-
molecular interaction networks and PubMed literature (24). Despite of those 
advancements, statistical association based studies are hard to differentiate drug efficacy 
from toxicity and even harder to provide a mechanistic view about why drugs have 
certain actions in specific disease conditions.  
 
Non-mechanistic approach contributes to a serious reliability and reproducibility issue in 
preclinical cancer drug research (25). A former cancer researcher at Amgen identified 53 
"landmark" publications -- papers in top journals, from reputable labs and 47 of the 53 
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could not be replicated(25). Mechanistic model-based analysis(26)  has been explored to 
aid in drug discovery to understand and predict the interaction of small molecule 
inhibitors with pathways. Take breast cancer for example. In a simple one-drug-one-
target scenario, tamoxifen can treat ER positive patients by inhibiting its target--over-
expressed estrogen receptor. However how to address the off-target effects (OTE) of a 
drug on the proteins downstream in the signaling pathways and then manipulate them for 
therapeutic purposes remains a big challenge.    
 
Khatri (27) reviewed the ten year pathway analysis and pointed out that the challenges of 
pathway based studies lie in the incompleteness of the pathway data which causes trouble 
for the current Pathway Topology (PT)-Based Approaches. Though HPD(28) collects 
human pathways from various sources, a disease specific pathway is not available. 
KEGG(29) covers only a limited list of disease pathway. For example KEGG doesn’t 
contain breast cancer pathway. Even with such a disease pathway, another challenge is to 
identify drug’s effect on the pathway proteins. There are over 40 drug-target (protein-
compound interaction) databases, according to Pathguide (30), (e.g. DrugBank(31), 
STITCH(32), and PharmGKB (33) et.al). DrugBank, for example, informs the researcher 
about interactions between drugs, physical drug target and proteins that metabolize the 
drug (31). However, these databases seldom directly inform the researcher about the 
directionality of a drug-target relation although this information may be scattered within a 
description or referenced text. Another difficulty is the inability to integrate the states of 
single proteins jointly into the higher level states of protein modules or pathway levels. 
The biological system is far from a homogenous one and thus makes a single general 
function, such as the sum of gene expression levels in a module, far from reality.  
 
Despite of those challenges, the computational prediction of drug efficacy could be 
particularly rewarding, especially in drug repositioning for personalized medicine(34) 
applications. The traditional drug development pharmaceutical product development 
requires at least 10 to 15 years and costs between $500 million and $2 billion(35). 
According to the U.S. FDA, up to 90% of all experimental drug compounds going 
through clinical trials failed to gain FDA approvals and drug efficacy accounts for 25-
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30%(36). Repositioning (37)refers to the identification and development of new uses for 
existing or abandoned drugs. It could greatly accelerate drug discovery because existing 
drugs have established clinical data(38). With recent advances in Omics and next 
generation sequencing techniques, elucidating the molecular basis of disease on a 
personalized level and thus tailing treatments accordingly has become an attainable goal. 
Drug failed at whole population may work at certain sub-population as personalized 
medicine(39). Drug repositioning for personalized medicine (34) aims to improve the 
productivity of current drug discovery pipelines and will benefit from the improved 
computational drug efficacy prediction.  
1.3 Drug Repositioning 
Discovering new indication for existing drugs, known as drug repositioning, is a hot topic 
in the translational bioinformatics field (17, 22, 40). Traditional drug discovery takes 
billions of dollars and an average of fifteen years to bring a new drug to the market (41). 
It’s estimated 90% of the drugs fail in the early stage of drug development(42). 
Repositioning of drugs already approved for human use could alleviate the cost 
associated with early stages and offer a shorter path for new approval(43). Both academia 
and pharmaceutical companies have achieved a number of successes by using drug 
repurposing. For example, the drug sildenafil, initially developed for pulmonary 
hypertension and angina pectoris, has been repositioned for erectile dysfunction 
indication. Thalidomide, originally applied for treatment of morning sickness and 
withdrawn from the market after causing thousands of severe birth defects, has been 
approved for indication in severe erythema nodosum leprosum(44). 
 
Current computational methods for drug repositioning include: (i) studying the structural 
similarity of each drug to their targets’ ligand set using chemoinformatics tools (45) or 
drug–drug and disease–disease similarity with machine learning methods(22), (ii) 
exploiting side-effect similarities (46), (iii) applying text-mining literature(23), or  (iv) 
matching drug and disease gene expression profiles (15, 17, 40, 47, 48). Most of the 
approaches can only be applied to well characterized drugs whose targets or structures 
are known. Expression profile based approaches are, on the other hand, more general and 
do not require prior knowledge of the drugs. 
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Lamb et al.(15) developed a public available database called The Connectivity Map 
(CMAP) containing a collection of transcriptional expression data from cell lines treated 
with small molecules. The reference database can be queried with gene signatures of 
interest, with a compound being identified if the genes in the signature are significantly 
modulated by that compound. Iorio et al.(40) constructed drug-drug similarity networks 
based on the gene expression profiles in the CMAP and proposed drug repositioning 
based on drug pairwise similarity. Hu and Agarwal(47) and Sirota et al.(17) extended the 
idea by paring drugs and diseases whose gene expression patterns are negatively 
correlated. They further showed that the anti-correlation relationships between the drugs 
and diseases can suggest novel therapeutics for existing drugs. 
 
 
Figure 1-1. Existing approaches for drug repositioning. 
All approaches are judged by two dimensions: 1) whether the approach is dependent on 
the dynamic expression profiles or the approach is based on existing knowledge; 2) 
whether the approach is based on drug chemical similarities or the approach is based on 
disease models.  In general effective medicine is based on specific disease model and 
gene expressions from the patients. 
9 
 
1.4 Organization of the Thesis 
The thesis is organized as follows: 
In Chapter 1, I provide an introduction of biomarker discovery and drug discovery, 
emphasizing the need for system level approaches. Coupling biomarker discovery and 
drug discovery is essential for identifying an effective treatment for patients.   
 Figure 1-2. A research road map for the thesis. 
 
Chapter 2 is based on my work at (49). We describe a simple yet generic computational 
framework based on protein interaction networks to perform and evaluate disease gene-
hunting, using colorectal cancer as a case study. We apply statistical measurements 
including specificity, sensitivity and Positive Predictive Value (PPV) to evaluate the 
performance of disease gene ranking methods, which we break down into seed gene 
Drug discovery involves disease biomarker identification and treatment 
recommendation (Chapter 1) 
 
Study how to effectively identify 
disease genes (Chapter 2) 
Part I: biomarker identification 
Build a central database for 
pathway biomarker discovery 
(Chapter 3) 
Develop a case study for 
biomarker identification for 
Diabetes (Chapter 4) 
Implement literature mining to 
build the disease-protein-drug 
connectivity map (Chapter 5) 
Part II: treatment recommendation 
Present the drug directionality 
database (DMAP) for drug 
repositioning (Chapter 6) 
Study drug repositioning beyond 
genomic level (Chapter 7) 
Discuss the future research direction of computational drug discovery both in 
genomics level and beyond genomics level.  (Chapter 8) 
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selection, protein interaction data quality and coverage, and network-based gene-ranking 
strategies. We discover that best results may be obtained by using curated gene sets as 
seeds, applying protein interaction data set with high data coverage and decent quality, 
and adopting variants of local degree methods.  
 
Chapter 3 is based on my work at (50). We develop an integrated online database, the 
Pathway And Gene Enrichment Database (PAGED), to enable comprehensive searches 
for disease-specific pathways, gene signatures, microRNA targets, and network modules 
by integrating gene-set-based prior knowledge as molecular patterns from multiple levels: 
the genome, transcriptome, post-transcriptome, and proteome. The online database we 
developed, PAGED (http://bio.informatics.iupui.edu/PAGED) is by far the most 
comprehensive public compilation of gene sets. In its current release, PAGED contains a 
total of 25,242 gene sets, 61,413 genes, 20 organisms, and 1,275,560 records from five 
major categories. Beyond its size, the advantage of PAGED lies in the explorations of 
relationships between gene sets as gene-set association networks (GSANs). Using 
colorectal cancer expression data analysis as a case study, we demonstrate how to query 
this database resource to discover crucial pathways, gene signatures, and gene network 
modules specific to colorectal cancer functional genomics.  
 
Chapter 4 is based on my work at (51). We present an innovative approach - network 
expansion and pathway enrichment analysis (NEPEA) for integrative microarray analysis. 
We assume that organized knowledge will help microarray data analysis in significant 
ways, and the organized knowledge could be represented as molecular interaction 
networks or biological pathways. Based on this hypothesis, we develop the NEPEA 
framework based on network expansion from the human annotated and predicted protein 
interaction (HAPPI) database, and pathway enrichment from PAGED. We use a recently-
published microarray dataset (GSE24215) related to insulin resistance and type 2 diabetes 
(T2D) as case study, since this study provided a thorough experimental validation for 
both genes and pathways identified computationally from classical microarray analysis 
and pathway analysis. We perform the NEPEA analysis for this dataset based on the 
results from the classical microarray analysis to identify biologically significant genes 
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and pathways. Our findings are not only consistent with the original findings mostly, but 
also obtained more supports from other literatures. Chapter 1-4 conclude the first part in 
this thesis about disease biomarker discovery.  
 
Chapter 5 is based on my work at (52). We assess drug pharmacological effect by 
assuming that “ideal” drugs for a patient can treat or prevent the disease by modulating 
gene expression profiles of this patient to the similar level with those in healthy people. 
Starting from this hypothesis, we build comprehensive disease-gene-drug connectivity 
relationships with drug-protein directionality (inhibit/activate) information based on a 
computational connectivity maps (C2Maps) platform. An interactive interface for 
directionality annotation of drug-protein pairs with literature evidences from PubMed has 
been added to the new version of C2Maps. We also upload the curated directionality 
information of drug-protein pairs specific for three complex diseases - breast cancer, 
colorectal cancer and Alzheimer disease. For relevant drug-protein pairs with 
directionality information, we use breast cancer as a case study to demonstrate the 
functionality of disease-specific searching. Based on the results obtained from searching, 
we perform pharmacological effect evaluation for two important breast cancer drugs on 
treating patients diagnosed with different breast cancer subtypes. The evaluation is 
performed on a well-studied breast cancer gene expression microarray dataset to portray 
how useful the updated C2Maps is in assessing drug efficacy and toxicity information.  
 
Chapter 6 is based on my work at (53). Critical to drug repositioning involves the reliable 
measurements of how drug affect disease proteins. We present a computational 
framework to address those challenges. First, we introduce the Drug directionality Map 
(DMAP) which consists of directed drug protein relationships for 328,676 drugs. We 
scale up the coverage of the database by 200 fold compared to experimental based 
Connectivity Map (CMAP) which suffers from limited drug coverage due to the 
experimental cost. DMAP enables systematic repositioning for 982 drugs and 622 
diseases. With two well-established drug-repositioning methods: drug similarity networks 
method and K-S scoring method, we demonstrate the feasibility of applying this valuable 
dataset for systematic drug repositioning. The results demonstrate that the DMAP 
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database is essential for computational drug repositioning research. Chapter 5 and 6 
conclude the drug repositioning work in the genomic level. 
 
In Chapter 7, I explore the possibility of drug repositioning beyond one dimension and 
beyond genomics level. We hypothesize that clinical side effects (SEs) provide a human 
phenotypic profile and can be translated into the development of in silico models for 
predicting novel drug combinations likely to be safe and efficacious. We build a 
prediction model based on the SE features and test it on a large independent drug 
combination set. The prediction achieves an accuracy of 0.94 and an AUC of 0.87. We 
demonstrate that such prediction power is not due to the confounding factors such as 
biased disease indications or drug targets. To explore the possibility of applying the 
prediction in practice, we train a rule-based model, namely the decision tree model, and 
successfully reduce the features to only three ‘black box’ SEs: pneumonia, hemorrhage 
rectum, and retinal bleeding, whilst maintaining an AUC of 0.80. Based on these results, 
we propose that avoiding combining drugs with any of these three serious SEs would 
have better chance of reducing the risks. Finally, we propose a “Two Steps Rule” so that 
it can help to identify potential safe co-prescriptions or novel fix-dose combinations 
while maintaining the efficacy.(54) 
 
In Chapter 8, I summarize all the research and contributions. I also discuss about the 
future research direction of computational drug discovery both in genomics level and 
beyond genomics level.  I highlight the significance of incorporating phenotypic features 
when building the prediction models. 
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Chapter 2. Analysis of Protein Interaction Network 
This section is based on the published work at (49). JYC guided the research team by 
providing ideas and feedback along the way, and revised the manuscript. HH integrated 
disease genes, generated the protein interaction network, ranked the disease proteins, and 
wrote the manuscript. JL helped with the specificity, sensitivity and PPV calculation and 
revised the manuscript.   
2.1 Introduction 
Disease gene finding is a central topic in biomedical research. If the causal genes are 
found for a disease, health care solutions may be developed to prevent disease 
occurrence, diagnose disease early, and make tailored treatment plans, e.g., in (55, 56). 
For nearly a century, there have been two approaches to discover genes related to a 
specific disease experimentally: biochemical analysis approach and genetic analysis 
approach (57). The first approach attempts to first separate and purify proteins 
characteristic of disease conditions in model organisms or tissues, and then study the 
disease-related proteins’ biochemical or biophysical altered properties that can be 
mapped to gene mutations. The second approach normally relies on first studying genetic 
markers identified in families of diseased populations, and then applying positional 
cloning techniques and linkage analysis to identify microsatellite markers, chromosomal 
aberrations, or DNA polymorphisms. However, experimental characterization of proteins 
or genes involved in diseases is a slow meticulous process. Today, even with advances of 
genomics technology, one third of all the genes and most of the disease related genes 
remain functionally uncharacterized (58). A promising new experimental technique is 
genome-wide association studies (GWAS), which may help identify candidate single-
nucleotide polymorphism (SNP) genetic markers associated with disease risks.  
 
While most computational approaches to disease gene finding rest on statistical 
association studies or computational sequence analysis, there are surging interests in 
taking advantage of molecular interaction networks. The concept is to put candidate 
genes and proteins in specific disease biology contexts defined by molecular interaction 
networks or biomolecular pathways, with which a researcher can infer functions of 
uncharacterized genes or proteins. Such disease biomolecular network context may be 
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particularly useful for the study of polygenic diseases such as cancer, in which 
conventional reductionist approaches are ineffective (55). In this new approach, disease 
networks are developed to rank disease relevance of genes/proteins based on properties 
such as node degrees (count of direct PPI connections to a node), closeness (path distance 
of a given node to all other nodes), or betweenness (count of geodesic paths that pass 
through a node). For example, Morrison et al. used gene expression network and gene 
ontology information to rank genes similar to Google’s PageRank method (59). Chen et 
al. were the first to propose a method that applied disease-specific protein-protein 
interaction (PPI) networks and modified local node degree measures to prioritize 
Alzheimer’s disease genes  (60).  
 
While many network-based disease-gene ranking methods have been developed recently, 
there has not been a consensus how to evaluate their performances. In this work, we 
describe a simple yet generic computational framework to perform and evaluate network-
based disease gene-hunting methods. Using colorectal cancer gene finding as a case 
study, we report how various seed gene selection, PPI data quality, and ranking strategy 
could affect final gene-finding results. We also defined how specificity, sensitivity, and 
positive predictive values (PPV) could be used for performance evaluation criteria. We 
choose colorectal cancer because it is the third leading cause of cancer death in the US 
and our current knowledge of colorectal cancer genes is limited, making our results to 
carry special significance. Next, we will describe our methods and report our findings.  
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2.2 Methods 
In Figure 2-1, we show an overview of the computational framework used in this study. It 
consists of two components: (1) Disease Gene Identification, in which we expand seed 
genes to disease-specific protein sub-network and subsequently generate a ranked list of 
disease-relevant genes; (2) Disease Gene Assessment, in which we quantitatively assess 
disease genes using statistical measurements including sensitivity, specificity and PPV. 
The relationships between the two components is the following: First, disease gene 
identification will be performed using a fixed set of gene-seeding, PPI sub-network 
construction, and disease gene ranking strategies; then, we evaluate how sensitivity, 
specificity, and PPV are affected by varying choices of seed genes, PPI networks, and 
ranking strategy.  
i. Seed Gene Selection 
We consider three sets of colorectal cancer-related genes collected from different 
resources as seeds, which are: (1) the CORE1 set (i.e. the curated genes), derived from 
human curated databases by querying the OMIM (61) and KEGG (62) database for 
“colorectal cancer” and manually curating the set of genes/proteins; (2) the CORE2 
set(i.e. the expressed genes), derived from high-throughput microarray data in the 
ONCOMINE (63) database by keeping only differentially expressed genes with p-
value<0.05 performed for colorectal cancer samples against controls; (3) the CORE3 
set(i.e. text mining genes), derived from the Comparative Toxicogenmics Database (CTD 
PPI Sub-network:
Construct human protein-
protein interaction sub-
network with different 
coverage and confidence.
Disease Genes: 
Select the top genes in 
sub-network using 
ranking strategy R. 
Seed Genes: 
Collect from curated 
databases, experiment 
results, and literature.
Disease Gene Identification Disease Gene Assessment
Positive Predictive Value: 
The probability of correct 
positive prediction.
Specificity: 
The percent of correctly 
identified non-disease genes.
Sensitivity: 
The percent of correctly 
identified disease genes.
 
Figure 2-1. Computational Framework for Disease Gene Identification and 
Assessment  
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(64)) by searching for colorectal cancer genes associated with >2 chemicals in the 
database.  
ii. Protein Interaction Sub-network Construction  
We expand seeds, using PPIs recorded in the Human Annotated and Predicted Protein 
Interactions (HAPPI) database (65) to construct colorectal cancer-specific PPI sub-
network. A unique feature of the HAPPI database is that the quality of PPIs comes with 
estimated confidence scores (a real value between 0 and 1) and star grades (an integer 
between 1 and 5). The higher the confidence score or the star grade number, the more 
likely the PPI is attributable to physical PPI events. In this study, we use PPI star grade to 
control disease-specific sub-network quality and coverage. We refer to the disease-
specific PPI sub-network constructed from HAPPI quality star grade n and above as PPI-
n. For example, PP1-3 includes all PPIs from HAPPI with quality grade of 3, 4, and 5.  
iii. Disease Gene Ranking Strategy 
We treat the disease gene ranking problem as a problem to calculate a weight for each 
protein in the disease-specific PPI sub-network. There are three ranking strategies being 
considered in this study: (1) Global degree strategy, in which we use the protein’s node 
degree in the global PPI-n network as the weight; (2) Local degree strategy, in which we 
use the protein’s node degree in the local (colorectal-specific) PPI-n network as the 
weight; and (3) Edge-weighted Promiscuous Hub subtraction (EPHS) strategy developed 
in Dr. Chen’s lab (60), which is a variant of local degree strategy adapted by penalize the 
impact of low-quality promiscuous protein hubs on ranks defined by the following 
formula:  
    (1) 
Here, p and q are indices for proteins in the constructed network NET. k is an empirical 
constant. conf(p, q) refers to confidence score in HAPPI Database. N(p, q) holds the value 
of 1 if the protein p interacts with q. The rp score is the weight calculated to rank each 
protein in the network. 
  
In addition, we use TOP_M to refer to the M highest ranked disease-relevant 
proteins/genes given by a specific disease gene ranking strategy.  
   NETq NETq qpNqpconfkpr )),(ln()),(ln(*
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iv. Disease Gene Assessment 
To evaluate the disease-related gene list, the sets of Gold Standard Positive (GSP) and 
Gold Standard Negative (GSN) are constructed as illustrated in Figure 2-2.  
 
The following measurements are calculated to evaluate the performance of each disease 
gene identification method: (1) Sensitivity, calculated as the percent of correctly 
identified disease genes |TOP_MGSP|/|GSP|; (2) Specificity, calculated as the percent 
of correctly identified non disease genes |GSN-(TOP_M-GSP)|/|GSN|; (3) Positive 
Predictive Value (PPV), calculated as the probability of correct positive predictions 
|TOP_MGSP|/| TOP_M |.  
2.3 Results 
We developed three colorectal cancer seeds: CORE1, consisting of 148 proteins; CORE2, 
consisting of 42 proteins; and CORE3, consisting of 721 proteins. With three choices of 
seeds gene selections (CORE1, CORE2, and CORE3), four PPI qualities (PPI-3, PPI-4, 
PPI-5, PPI-1), three ranking strategies (EPHS, Local Degree, Global Degree), we tested 
different combinations to conduct the disease gene findings and assessment for colorectal 
cancer.  
 
 
 
 
 
ALL
CORE3
CORE1 CORE2
 
Figure 2-2. Gold standard construction for disease gene assessment.  
As shown in the striped area, GSP= 
(CORE1CORE2)(CORE1CORE3)(CORE2CORE3).  As shown in the gray area, 
GSN=ALL-(CORE1 CORE2 CORE3). Note that ALL refers to all HAPPI human 
proteins. 
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i.  Effect of Various Seed Gene Selection Methods 
In Figure 2-3, we show how seed selections affect the ranking results. In this experiment, 
we used PPI-3 as PPI network data source and the EPHS disease protein ranking method. 
The ranking index on the x-axis refers to a number, TOP_M, used to indicate the number 
of all rank-ordered proteins in a given expanded protein set consisting of both seed 
proteins and PPI-expanded disease sub-network. PPV for the initial top-10 or top-20 
proteins for both core-1 and core-2 seeded strategies were at 0.7-0.8 range, suggesting 
high predictive power of top-ranked proteins for disease-relevance. As ranking index 
increases, PPV decrease for all core seeded strategies. However, the performance for 
core-1 is superior to both core-2 and core-3. This is perhaps due to the highly curated 
nature of core-1 seeds as compared with possible noises introduced by Omics data for 
core-2 and text mining data for core-3. Core-3 shows an overall poorer PPV performance, 
particular within top-20 compared with core-1 and core-2. Beyond ranking index of 250, 
all core seeded strategies converged to low PPV within 0.15. Therefore, the relatively 
high predictive powers of all disease gene rankings seem to be restricted to the top 50.  
 
 
 
 
 
 
 
 
Figure 2-3. PPV performance using different seed choices. 
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ii. Effect of Various PPI Data Quality and Coverage 
In Figure 2-4, we show how PPI data used for network expansion affect the ranking 
results. In this experiment, we compared results using PPI-1, PPI-3, PPI-4, and PPI-5, 
using core1 as seeds and the EPHS ranking method. All PPI-n except for PPI-5 showed a 
similar trend of decreasing PPV. Again, the relatively high predictive powers (PPV>0.5) 
seem to be achieved at the top 50, except for PPI-5, then continue to decrease to very low 
levels (PPV<0.15) beyond a ranking index>400. It’s counter-intuitive that PPI-5’s 
performance, being the poorest, has a rising phase from ranking index between 10 and 50 
before decreasingly significantly. This may be primarily due to the poor coverage of true 
colorectal cancer proteins in current physical PPI data sets representative of PPI-5 until 
enough proteins are covered in the top 40 or 50 set. Therefore, data coverage seems quite 
important in gene ranking performance overall. Also, at least in the top 10 case, the fact 
that PPI-3 has the best PPV of 0.8 over PPI-1 that has much higher data coverage suggest 
that PPI data quality is also important to discover disease genes in the most highly ranked 
protein set. Therefore, balanced data coverage and quality are essential for disease gene 
finding from such networks.  
 
iii. Effect of Various Disease Gene Ranking Methods 
In Figure 2-5, we show how the choices of different ranking methods affect the ranking 
results. The results are performed by fixing seed protein to core1 and using PPI-5 for the 
expansion network. EPHS and Local Degree methods performed equally, while global 
degree performed extremely poor—although by sharing similar performance trend of the 
top-performing methods. The trend for all methods shows two phases: a PPV rising phase 
 
Figure 2-4. PPV performance using different PPI-n networks. 
 
20 
 
from top 10 to top 60-80; and a PPV decreasing phase from top 80 onwards. The 
separations of two phases are likely due to balanced PPI data coverage and quality as 
explained earlier.  
 
iv. Sensitivity and Specificity Comparisons of Top Disease Gene Ranking Methods. 
We further compared the sensitivity and specificity performances for the best two disease 
gene ranking methods, EPHS and Local Degree.  
 
Figure 2-6 shows a comparison of their specificity (on the y-axis) performance 
distributed over different ranking index ranges (on the x-axis). The specificity 
performances of both methods are quite good overall, even at top 100 range 
(specificity>0.9). The EPHS ranking method is slightly better (more specific) than Local 
Degree ranking method. This is primarily because local degree method cannot distinguish 
nodes with the same number of node degrees, particularly when the node degree drops to 
small numbers such as 2 or 3 in the high ranking index region.  
 
Figure 2-5. PPV performance using different disease gene ranking methods.  
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Figure 2-7 shows a comparison of their sensitivity (on the y-axis) performance distributed 
over different ranking index ranges (on the x-axis). The sensitivity performances of both 
methods are decent overall after ranking index range of top 80 (sensitivity>0.75). The 
local degree ranking method is slightly better (more sensitive) than EPHS ranking 
method. The reason that local degree method performed better than EPHS ranking 
method is that there are many tied genes in local degree method due to their sharing the 
same node degrees. However, since most rankings should be performed in the low 
ranking index region, this slight loss of sensitivity for EPHS method can be ignored.  
 
2.4 Conclusions 
In this work, we performed disease gene finding from protein-protein interaction 
networks specific to colorectal cancer. We examined the effects of different seeds, 
different PPI data quality, and different disease gene ranking methods on the final 
 
Figure 2-6.  A comparison of specificity performance between the EPHS and Local 
Degree ranking methods. 
 
Figure 2-7.  A comparison of sensitivity performance between the EPHS and Local 
Degree ranking methods. 
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performance of the task. While all of these parameters may impact the final performance,  
our results show that (1) the initial quality of seeds should be based on prior curated 
knowledge as much possible, with Omics results being the next choice and text mining 
results being the last resort; (2) disease gene ranking should be performed using PPI data 
with reasonable quality but as high data coverage as possible; (3) the ranking algorithm 
that takes advantage of local network parameters should be chosen over those using 
global network parameters. There are several limitations to our current research 
approach. For example, the gold standard positive set of genes used for evaluation had to 
be built by considering seed gene sets used for research studies due to convenience of 
computation. The observations made for this framework should be carefully validated in 
other disease contexts before they be generalized. 
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Chapter 3. Pathway and Gene-set Enrichment Database 
This section is based on the published work at (50). JYC conceived of this work, guided 
the research team, and revised the manuscript. HH integrated disease-gene association 
data, developed the website, designed the case studies and wrote the manuscript. XW 
participated in the idea initiation, framework development, data quality control, case 
studies, and manuscript writing. MS integrated various pathways, microRNA, and gene 
signature data. SNM reviewed the evolvement on pathway analysis and gene-set 
enrichment analysis. RP helped with the database management and maintenance. KFM 
tested the website, provided valuable suggestions for substantial improvements, and 
revised the manuscript. PW assisted with website maintenance.   
3.1 Introduction 
Pathway analysis and gene-set enrichment analysis are both widely-used methods to 
identify significant molecular expression patterns from high-throughput data (27). Over 
the last decade, biological pathways have provided natural sources of molecular 
mechanisms to develop diagnosis, treatment, and prevention strategies for complex 
diseases (66-68). The various and massive functional genomics data are effectively 
analyzed by gene-set enrichment methods instead of individual gene analysis (69-72). 
Pathway analysis and molecular signature discovery continue to reveal the association 
between genotypes and phenotypes, which are simply called molecular profiling or 
molecular phenotypes. At present, researchers intend to combine pathway and gene-set 
enrichment approaches and network module-based approaches to identify crucial 
relationships among different molecular mechanisms (27). 
 
As sources of prior knowledge for molecular mechanisms, biological pathway databases 
are heterogeneous, cross multiple levels, and lack annotations (67). Different pathway 
databases may yield divergent results from the same input data. When different databases 
yield similar results, applying multiple pathway data sources in a single analysis can 
generate a measure of validation. Unlike candidate pathway analysis, genome-wide 
pathway analysis does not require prior biological knowledge. In addition, genome-wide 
pathway analysis can reveal gene interactions across different diseases (67, 73) and 
multiple pathways (67, 74, 75). Other studies based on an online integrated human 
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pathway database (HPD) also provided associations between different pathways with 
diverse types, sizes, and sources (28, 76) on specific phenotypes. Although these efforts 
have greatly improved the efficiency of pathway analysis, our knowledge of biological 
pathways is still far from complete. 
 
Gene signature data from the transcriptome level offers a complementary source of 
information to complete pathway knowledge. In a recent review, Khatri et al. (27)  
categorized pathway analysis into three generations of approaches: the first-generation 
“over-representation analysis” (ORA) approaches, the second-generation “functional 
class scoring” (FCS) approaches, and the third-generation “pathway topology” (PT) 
approaches. To overcome the limitations of ORA approaches (gene-level statistics), FCS 
approaches, such as gene-set enrichment analysis (GSEA) (70), were devised to include 
overall changes of gene expressions in each pathway/gene set (pathway-level statistics). 
Third generation approaches also include overall changes of gene expressions based on 
pathway topology—that is, their upstream/downstream positions within each pathway. 
Although these third generation approaches were meant to change our understanding of 
the underlying mechanisms of pathways, they lack information necessary to achieve this: 
the interdependence between pathways. Annotated knowledge from genome, 
transcriptome, post-transcriptome, and proteome levels can assist pathway and gene-set 
enrichment analysis. 
 
Multi-level, multi-scale, knowledge-guided enrichment analysis can enable molecular 
phenotype discovery for specific human diseases. Currently, the acquisition of prior 
knowledge and systems modeling poses a challenge for developing tools that go beyond 
third-generation pathway analysis for disease-specific molecular profiling. Prior 
knowledge acquisition requires attention to updates and improves the available 
annotations with descriptive knowledge from multiple levels, especially for information 
on pathway microenvironment (“condition-, tissue-, and cell-specific functions of each 
gene”) (27, 67). Systems biology modeling must incorporate data from the view of 
systems biology to build systems with multiple scales, which can be used to generate 
hypotheses that will give detailed and accurate predictions of changes in systems. Both 
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aspects of this challenge will be addressed by building a database not only containing 
disease-associated genes, transcript factors, proteins, and microRNAs, but also by 
organizing their relationships within and between pathways, gene signatures, and any 
gene sets from existing experiments or papers. 
 
To meet the new challenges of molecular phenotype discovery, we developed in this 
work an integrated online database, the Pathway And Gene Enrichment Database 
(PAGED), to enable comprehensive searches for disease-specific pathways, gene 
signatures, microRNA targets, and network modules, by integrating gene-set-based prior 
knowledge as molecular patterns from multiple levels—the genome, transcriptome, post-
transcriptome, and proteome. The new database can provide the following benefits to 
biological researchers. First, the new database consists of disease–gene association data, 
curated and integrated from Online Mendelian Inheritance in Man (OMIM)(77) database 
and the Genetic Association Database (GAD)(78); therefore, it has the potential to assist 
human disease studies. Second, as of March 2012 it also contains all current compiled 
gene signatures in Molecular Signatures Database (MSigDB)(72) and Gene Signatures 
Database (GeneSigDB)(71). Third, it further integrates with microRNA-targets from 
miRecords(79) database, signaling pathways, protein interaction networks, and 
transcription factor/gene regulatory networks, partially based on data integrated from the 
Human Pathway Database (HPD) (28)and the Human Annotated and Predicted Protein 
Interaction (HAPPI)(80) database. All gene sets or pathways are annotated with 
molecular interaction details whenever available. We integrated the following version of 
the database OMIM(77) (Feb. 2012), GAD(78) (Aug. 2011), GeneSigDB(71) (v. 4.0, 
Sept. 2011), MSigDB(72) (v. 3.0. Sept.  2010), HPD(28) (2009), HAPPI (80)(v. 1.4) and 
miRecords(79) (Nov. 2010), which are the latest versions available. An advantage of our 
work lies in its representation of relationships between pathways, gene signatures, 
microRNA targets, and/or network modules. These gene-set-based relationships can be 
visualized as a gene-set association network (GSAN), which provides a “roadmap” for 
molecular phenotype discovery for specific human diseases. Using colorectal cancer 
expression data analysis as a case study, we demonstrate how to query PAGED to 
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discover crucial pathways, gene signatures, and gene network modules specific to 
colorectal cancer functional genomics. 
3.2 Methods 
i. Data sources 
We show an overview of the data integration process in Figure 1. Gene-set data were 
collected, extracted, and integrated from five major categories. The pathway data sources 
were from HPD (28), which has integrated 999 human biological pathway data from five 
curated sources: KEGG, PID, BioCarta, Reactome, and Protein Lounge. The genome-
level disease gene relationships were from OMIM (77) and GAD (78); the transcriptome-
level gene signatures were from MSigDB (72) and GeneSigDB (71); the post-
transcriptome-level microRNA data were from miRecords (79); and the proteome level 
data was from an integrated protein interaction database HAPPI (80), which has 
integrated HPRD, BIND, MINT, STRING, and OPHID databases. 
ii. Gene-set data integration 
We treat as gene sets all groups of genes, including disease-associated genes, pathway 
genes, gene signatures, microRNA-targeted genes, and PPI sub-network modules. The 
raw files from those data sources have various formats including plaintext, XML, and 
table. We have written Perl/Java parsers to convert them into a common tab-delimited 
textual format to ensure syntactic-level data compatibility. To integrate across different 
databases, we mapped the gene/protein IDs in all databases to official gene symbols. The 
gene-set gene data is stored in the backend ORACLE11g relational database. As of the 
current release, PAGED contained a total of 25,242 gene sets, 61,413 genes, 20 
organisms, and 1,275,560 records. All gene set members are represented by the official 
gene symbols. All PAGED gene sets were assigned unique PAGED-specific identifiers.  
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iii. Online software designing 
The PAGED platform follows a multi-tiered design architecture. The backend was 
implemented as PL/SQL packages on an Oracle 11g database server and the PAGED 
application middleware was implemented on the Oracle Application Express (APEX) 
server, which bridged between the Apache webserver and the Oracle database server.  
iv. Gene-set similarity measurement 
Referring to the pathway similarity definition introduced in (28), the similarity score Si, j 
of two different gene sets is defined by the following formula: 
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Figure 3-1. The workflow of gene-set data integration and the basic statistics of 
gene-set data sources. 
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Here, Pi and Pj denote two different gene sets, while |Pi| and |Pj| are the number of genes 
in each of these two gene sets. Their intersection Pi∩Pj denotes a common set of genes, 
while their union Pi∪Pj is calculated as |Pi|  |Pj|  |Pi∩Pj|. Here, α is a weight coefficient 
among [0, 1], which is used to count varying degree of contributions from calculations 
based both on the overlap (left item SL) and the cover (right item SR). SL is well-known as 
the Jaccard coefficient (81), which is often used to evaluate the similarity between two 
sets (82). When a larger gene set covers a smaller one, we expect their similarity score to 
be high enough to identify them. In this situation, although the left item SL is a small 
number, the right item SR will be counted as 1.0 to make the final similarity score higher 
according to our definition in Equation (1), when taking an appropriate α value. We 
found that when α fell in the interval of [0.7, 0.9], the score distribution would be close to 
a Poisson distribution. As we know, a Poisson distribution expresses the probability of a 
number of events occurring during a fixed period of time if these events occur with a 
known average rate and are time-independent since the last event. Therefore, we chose 
the middle value, α = 0.8, for the rest of the analysis. Our previous HPD paper (28) also 
validates the choice of 0.8 as the pathway similarity measurement.  
v. Microarray data 
Here we use colorectal cancer (CRC) expression data analysis as a case study to show 
how to discover crucial pathways, gene signatures, and gene network modules specific to 
colorectal cancer functional genomics. We downloaded a colorectal cancer microarray 
dataset GSE8671 from Gene Expression Omnibus, GEO 
(http://www.ncbi.nlm.nih.gov/geo/) (83). This microarray dataset compared the 
transcriptome data of 32 prospectively collected adenomas with those of the normal 
mucosa from the same individuals. Hence, we have 32 CRC samples and 32 normal 
samples. We used maximal expression values for the same proteins mapped from 
different Probe IDs, the Affy package in BioConductor for quantile normalization, the 
built-in MicroArray Suite (MAS5) for background correction, and Limma in 
BioConductor for differential analysis, the result of which is represented as fold changes 
(FC) of CRC samples vs. normal samples.  
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vi. Differential gene-set expressions and gene-set association network 
We use ABS_FC to denote the absolute value of fold change for each gene. We then 
define differential gene-set expressions here as 
NORM_ABS_FC: The p*-norm of ABS_FC of all the available differential gene 
expressions in a gene set. 
Usually, p-norm =       
      
 
  
For unification, we modify it as 
p*-norm =   
 
 
     
       
 
    (2) 
In the implementation, p = 6 performs the best at accentuating highly differential 
expressions in a gene set. 
To visualize the relationships between gene sets, we define a gene-set association 
network (GSAN) as a network of associations between different gene sets, in which the 
network element representation is as follows: 
• Node: Gene set 
• Edge: Association between two gene sets 
• Node size: Gene-set scale (Counting genes in each gene set) 
• Node color: Differential gene-set expression (NORM_ABS_FC) 
• Node line color: Gene-set data source 
• Edge width: Similarity score 
3.3 Results 
i. Database content statistics 
Table 3-1 lists the detailed statistics for each data source and the overlap between each 
pair. For example, MSigDB contains 30,525 genes and GeneSigDB contains 36,791 
genes. The number of overlapping genes between these two databases is 17,209. We 
found a synergistic effect from integrating these two signature databases, resulting in 
greatly increased gene-set coverage. The same effect was observed for all the remaining 
pair comparisons. These data sources proved to be complementary. 
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Table 3-1. Number of overlapping genes between different data sources 
 OMIM GAD MSigDB GeneSigDB miRecords HPD HAPPI* 
OMIM 9012 1862 3489 2792 231 2559 3849 
GAD  7293 6821 6450 432 3202 4922 
MSigDB   30525 17209 759 6229 10677 
GeneSigDB    36791 900 5904 10395 
miRecords     1395 443 725 
HPD      12228 10512 
HAPPI       21955 
* Only PPIs of over 3-star quality are considered here; to calculate the overlap, protein IDs from 
HAPPI have been first converted to gene symbols. 
 
ii. Gene-set scale distributions 
The gene-set scale can reflect the integrality of information content of a biological topic. 
In this study, we define gene-set scale as the number of molecules (i.e., gene symbols) in 
a gene set. We performed a statistical analysis of the gene-set scale distributions of both 
PAGED and of its individual data sources. Figure 3-2 shows that each data source taken 
by itself is not very scale-free, especially for OMIM, GAD, and miRecords for higher 
 
Figure 3-2. Gene-set scale distributions for PAGED molecule data 
A gene-set scale refers to the number of molecules (i.e., genes) involved in a given 
gene set. The frequency on the y-axis refers to the count of all gene sets falling into 
the category of a particular gene-set scale size on the x-axis. The distributions are 
plotted under log scale for both the x-axis and y-axis. The linear trend line in red 
represents linear regression of PAGED distribution and the linear equation and its R-
Square are listed. 
31 
 
scales and HPD, GeneSigDB, and MSigDB for lower scales. The scale distribution of 
PAGED is relatively scale-free on both the low end and the high end with a linear 
regression R-squared of 0.88. Additionally, the distribution of PAGED always lies above 
those of its data sources, indicating that the integration has enriched the number of gene 
sets in all scales instead of exhibiting a bias towards one particular scale. These 
observations indicate that the integration process of PAGED has resulted in a database 
that can take account of different gene set scales. 
iii. Online functionalities 
In Figure 3-3, we show the user interfaces of the PAGED website. It supports both 
disease-based search and user-defined gene-list search. If users search the disease term in 
the home page (Figure 3-3A), PAGED will retrieve a list of related gene sets by directly 
matching the disease term with all the gene-set names; if users instead search a disease 
term in the advanced search page (Figure 3-3D), PAGED will first retrieve disease-
relevant genes from OMIM and GAD and then use those genes to query the whole 
database, which will retrieve a gene-set list based on disease gene profiles that is more 
comprehensive than that of either OMIM or GAD individually. Users can also search 
PAGED using multiple genes in the home page (by delimiting them with a comma) to 
retrieve a list of related gene sets with the hits number and similarity scores (Figure 3A). 
In addition, users can upload a file of their genes with one gene per line on the advanced 
search page (Figure 3-3D) to perform the gene-based search. In the advanced gene-based 
search (Figure 3-3D), user can also perform an organism specific search though the 
majority of the gene-sets are human related.  All the gene sets are hyperlinked to the 
original database, where user can further examine the detailed annotations of that specific 
gene set.  
 
Upon executing the queries, PAGED can retrieve a list of related gene sets in an HTML 
table (Figure 3-3B, C) with their specific organism information included, which are 
downloadable as a comma-separated value (CSV) file. On the same page, there are links 
for downloading all the genes in those gene sets and the association between each gene 
set. In the gene set association downloading page, a simple heat map is provided for the 
visualization of gene set similarities. 
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Figure 3-3. An overview for the core functionality of the online PAGED website 
(A) The PAGED home page providing search by either disease name or gene list; (B) 
a webpage containing the list of gene sets retrieved as a result of a disease query; (C) 
a webpage containing the list of gene sets retrieved as a result of a gene list query; 
(D) an advanced search page in which the user can either search disease name or 
upload a gene-list to search; (E) a browse page listing the gene sets, their data source 
and number of genes. 
 
33 
 
iv. Case studies 
The following case studies use colorectal cancer expression data analysis as a case study 
to demonstrate how to discover crucial pathways, gene signatures, and gene network 
modules specific to colorectal cancer functional genomics. 
 
Case study I: Searching disease-associated gene sets based on gene-set names 
Using the standard query box provided at the PAGED home page, one can search for 
colorectal cancer in all biological gene sets. PAGED returns a list of gene sets, which 
can be ordered by decreasing number of genes contained by each gene set. In total, 45 
gene sets from three data sources (i.e., OMIM, GAD and KEGG) have been retrieved. 
Not surprisingly, most of them are disease-related gene sets from either OMIM or GAD. 
Only 1 (i.e., “Colorectal cancer pathway”) out 45 is from KEGG. The top 10 search 
results are listed in Table 3-2. 
 
Table 3-2. Top 10 search results by querying colorectal cancer at the home page 
Gene-set Name # of Genes Data Source 
Colorectal cancer 433 GAD 
Colorectal cancer 134 KEGG 
Colorectal cancer 14 OMIM 
Colorectal cancer, somatic 12 OMIM 
Colorectal cancer, hereditary non-polyposis, type 8 7 OMIM 
Colorectal cancer, susceptibility to 7 OMIM 
Colorectal cancer, hereditary non-polyposis, type 6 6 OMIM 
Breast and colorectal cancer, susceptibility to  5 OMIM 
Colorectal Cancer 5 GAD 
 
Case study II: Searching disease-associated gene sets based on gene-set components 
Next, a user can search with the same term colorectal cancer on the advanced search 
page, which uses the disease’s gene profile to search for gene sets. PAGED first obtained 
203 colorectal cancer related genes from OMIM and GAD. Then, it used those genes to 
retrieve a total of 4,932 gene sets with at least 2 hits. Since we were more interested in 
gene sets other than disease terms, we excluded those gene sets from OMIM and GAD 
for further analysis. To rule out the possibility that those gene sets were hit randomly, we 
did a Fisher’s exact test to calculate the p-value between those 203 genes and every 
retrieved gene set. Finally, we obtained 3,879 gene sets with a p-value <0.05 and hits ≥2. 
34 
 
These gene sets are from all data sources, including MSigDB, GeneSigDB, miRecords, 
and all pathway data sources from HPD. Both the number of gene sets and their variety 
support the conclusion that advanced disease search based on gene profiles are more 
comprehensive than a simple disease search. For other disease query, a similar procedure 
will be followed to calculate the p-value and the number of hits on the fly. 
 
Table 3-3 shows the top results ranked by decreasing number of hits from each data 
source. Protein Lounge suggests “Molecular Mechanisms of Cancer,” “Akt Signaling,” 
and other important pathways in colorectal cancer; BioCarta suggests “wnt signaling 
pathway”; and NCI Nature curated suggests “Canonical Wnt signaling pathway.” These 
are all very important pathways in colorectal cancer development (84). Similarly, 
“Colorectal cancer” and “p53 signaling pathway” from KEGG, 
“SIGNAL_TRANSDUCTION” and “KEGG_PATHWAYS_IN_CANCER” from 
MSigDB, and cancer-related signatures/microRNA from GeneSigDB/miRecords reveal a 
comprehensive picture of the important gene sets involved in colorectal cancer. Thus, the 
results of the advanced search yield more insights about colorectal cancer mechanisms 
than those of the simple search. 
 
Table 3-3. Top search results of colorectal cancer advanced search  
Gene-set Name Hits P value FDR Data Source 
Molecular Mechanisms of Cancer  38 2.48E-17 7.04E-10 Protein Lounge 
PI3K Signaling  33 2.01E-13 7.04E-10 Protein Lounge 
Akt Signaling 27 9.6E-13 7.04E-10 Protein Lounge 
ERK Signaling 24 1.53E-10 7.04E-10 Protein Lounge 
GSK3 Signaling 23 1.32E-13 7.04E-10 Protein Lounge 
inactivation of gsk3 by akt causes accumulation of 
b-catenin in alveolar macrophages 9 3.7E-11 7.04E-10 BioCarta 
atm signaling pathway 8 6.28E-11 7.04E-10 BioCarta 
wnt signaling pathway 7 7.7E-09 7.04E-10 BioCarta 
cell cycle: g2/m checkpoint 7 2.14E-08 7.04E-10 BioCarta 
cell cycle: g1/s check point 7 2.14E-08 7.04E-10 BioCarta 
Canonical Wnt signaling pathway 8 9.24E-10 7.04E-10 NCI-Nature  
Presenilin action in Notch and Wnt signaling 8 3.16E-08 7.04E-10 NCI-Nature 
Plasma membrane estrogen receptor signaling 7 1.41E-08 7.04E-10 NCI-Nature  
FOXM1 transcription factor network 7 2.48E-07 7.04E-10 NCI-Nature  
LPA receptor mediated events 7 1.45E-06 7.04E-10 NCI-Nature  
Metabolism of xenobiotics by cytochrome P450 20 3.3E-25 7.04E-10 KEGG 
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Drug metabolism - cytochrome P450 17 4.96E-21 7.04E-10 KEGG 
Bladder cancer 15 3.29E-18 7.04E-10 KEGG 
Cytokine-cytokine receptor interaction 15 1.39E-06 7.04E-10 KEGG 
Colorectal cancer 14 4.43E-14 7.04E-10 KEGG 
p53 signaling pathway 14 4.92E-14 7.04E-10 KEGG 
Prostate cancer 14 1.66E-12 7.04E-10 KEGG 
Xenobiotics 5 3.32E-08 7.04E-10 Reactome 
Formation of incision complex in GG-NER 5 5.75E-06 7.04E-10 Reactome 
Global Genomic NER (GG-NER) 5 5.75E-06 7.04E-10 Reactome 
Dual incision reaction in GG-NER 5 5.75E-06 7.04E-10 Reactome 
Exocytosis of Alpha granule 5 0.000217 1.95E-08 Reactome 
SIGNAL_TRANSDUCTION 55 8.36E-28 7.04E-10 MsigDB 
BIOPOLYMER_METABOLIC_PROCESS 49 4.16E-22 7.04E-10 MsigDB 
KEGG_PATHWAYS_IN_CANCER 43 9.9E-46 7.04E-10 MsigDB 
NUCLEOBASENUCLEOSIDENUCLEOTIDE_A
ND_NUCLEIC_ACID_METABOLIC_PROCESS 41 2.16E-20 7.04E-10 MsigDB 
NUCLEUS 41 1.8E-18 7.04E-10 MsigDB 
Immune_Kong10_5640genes_ImmPort_Comprehe
nsiveListofImmune-RelatedGenes 114 3.61E-49 7.04E-10 GeneSigDB 
Lymphoma_Melendez05_4229genes 81 1.57E-39 7.04E-10 GeneSigDB 
Breast_Farmer05_3198genes_basal_apocrine_lumi
nal 66 1.08E-21 7.04E-10 GeneSigDB 
Ovarian_Crijns09_2394Genes_17PathwayPredicto
r 57 7.94E-30 7.04E-10 GeneSigDB 
StemCell_Nilsson07_3742genes 45 4.86E-07 7.04E-10 GeneSigDB 
hsa-miR-19a 3 1.49E-05 8.43E-09 miRecords 
[hsa-miR-21] 3 0.000116 8.43E-09 miRecords 
hsa-miR-204 3 0.000164 1.95E-08 miRecords 
hsa-miR-21 3 0.000953 2.72E-07 miRecords 
hsa-miR-125b 3 0.003089 2.72E-07 miRecords 
 
Case study III: Searching gene sets similar to user-defined query gene sets 
To use the gene-based search from PAGED, we first analyzed a colorectal cancer 
microarray dataset GSE8671 with BioConductor to identify the differential genes. We 
selected the top 100 genes ranked by the absolute fold change with p-values less than 
0.05. After querying PAGED with those 100 genes, we obtained 1,707 gene sets, out of 
which 1,152 also satisfied Fisher’s exact test of a p-value less than 0.05. Those gene sets 
span from all the data sources except BioCarta and miRecords. Table 4 lists the top 
results ranked by the number of hits. Most of them are cancer-related gene sets. 
Specifically, “SABATES_COLORECTAL_ADENOMA_DN” and 
“SABATES_COLORECTAL_ADENOMA_UP” from MSigDB and 
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“Intestine_Vecchi07_1024genes” and “Colon_Kim04_235genes” from GeneSigDB 
supports the importance of those 100 query genes to colorectal cancer. This case study 
also shows the complementary nature of MSigDB and GeneSigDB and thus the benefit of 
integrating them, which has also been proved by (85) 
 
Case study IV: Building disease-specific gene-set association networks (GSANs) based 
on gene-set similarities 
With the unique top 50 gene sets related to colorectal cancer from disease search and 
gene search (Table 3-3 and Table 3-4), we next investigated the gene-set associations 
between them; 863 associations were found by overlapping the gene symbols between 
each pair of gene sets, out of which 642 also satisfied Fisher’s exact test of a p-value and 
 
 
Figure 3-4. CRC-specific gene-set association network (GSAN) on the top gene 
sets from colorectal cancer study.  
Node size: Gene-set scale (Counting genes in each gene set); Node color: Gene-set 
data source; Edge width: Similarity score (≥ 0.1). All gene sets are highly connected to 
each other, suggesting their collaborative functions in colorectal cancer. 
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FDR less than 0.05. A network visualization using Cytoscape (86) is shown in Figure 3-4. 
Most of those gene sets are connected to one another, and a few share a large number of 
genes, suggesting that they form a collaborative unit in colorectal cancer. 
 
Table 3-4. Top search results of gene-based search from colorectal microarray 
datasets 
Gene-set Name Hits P value FDR Data Source 
SABATES_COLORECTAL_ADENOMA_DN 58 4.57E-96 2.76E-10 MsigDB 
Breast_Farmer05_3198genes_basal_apocrine_lumi
nal 35 2.91E-13 2.76E-10 GeneSigDB 
SABATES_COLORECTAL_ADENOMA_UP 34 1.62E-57 2.76E-10 MsigDB 
Immune_Kong10_5640genes_ImmPort_Comprehe
nsiveListofImmune-RelatedGenes 34 3.56E-08 2.76E-10 GeneSigDB 
Leukemia_Pellegrini08_2692genes 32 1.28E-15 2.76E-10 GeneSigDB 
Intestine_Vecchi07_1024genes 28 3.91E-23 2.76E-10 GeneSigDB 
Viral_Buonomo11_5307genes 25 6.45E-05 0.000109 GeneSigDB 
SMID_BREAST_CANCER_LUMINAL_B_DN 23 4.16E-19 2.76E-10 MsigDB 
Lymphoma_Melendez05_4229genes 22 2.03E-06 2.76E-10 GeneSigDB 
Colon_Kim04_235genes 21 5.18E-30 2.76E-10 GeneSigDB 
Breast_Parker09_1918genes_IntrinsicGenes_Com
pilation 21 1.18E-08 2.76E-10 GeneSigDB 
  
Case study V: Prioritizing disease-associated gene sets by using differential gene-set 
expressions 
First, the differential gene expression value (ABS_FC) for each gene in a gene set is 
calculated from the differential analysis based on the microarray data GSE8671. Second, 
the differential gene-set expression value (NORM_ABS_FC) for each gene set in the 
CRC-specific GSAN is calculated by using Equation (2). Third, a CRC-specific GSAN 
with differential gene-set expressions is shown in Figure 3-5, in which node size 
represents gene-set scale (Counting genes in each gene set); node color represents 
differential gene-set expression (NORM_ABS_FC); node line color represents the gene-
set data source; and edge width represents the similarity score. By considering 
differential gene-set expressions for each gene set, we prioritize top-selected gene sets as 
shown in Table 3-5. Most of top-ranked gene sets are closely related to colon tissue, 
colorectal cancer, or other cancers, which implies that the database can not only support 
comprehensive disease-associated gene-set searching and browsing, but also accurate, 
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disease-specific gene-set prioritizing by using the concept of differential expressions at 
the gene-set level. 
 
Table 3-5. Top 20 gene sets ranked by differential gene-set expressions in the CRC-
specific gene-set association network (GSAN) 
Gene-set name Scale Data 
Source 
NORM_ABS_FC 
Colon_Kim04_235genes 151 GeneSigDB 48.58225017 
SABATES_COLORECTAL_ADENOMA_DN 292 MsigDB 43.9233159 
SIGNAL_TRANSDUCTION 1598 MsigDB 32.5957784 
Leukemia_Pellegrini08_2692genes 2122 GeneSigDB 31.65148925 
SABATES_COLORECTAL_ADENOMA_UP 142 MsigDB 31.65000681 
Breast_Parker09_1918genes_IntrinsicGenes 
_Compilation 
1734 GeneSigDB 20.85621131 
Lymphoma_Melendez05_4229genes 2570 GeneSigDB 19.38449282 
Breast_Farmer05_3198genes_basal _apocrine 
_luminal 
3125 GeneSigDB 18.93820407 
SMID_BREAST_CANCER_LUMINAL_B_DN 648 MsigDB 18.13762096 
Intestine_Vecchi07_1024genes 796 GeneSigDB 16.68882931 
Ovarian_Crijns09_2394Genes 
_17PathwayPredictor 
1586 GeneSigDB 15.29529767 
hsa-miR-204 19 miRecords 14.37015815 
StemCell_Nilsson07_3742genes 3624 GeneSigDB 12.47045771 
Immune_Kong10_5640genes_ImmPort 
_ComprehensiveListofImmune-RelatedGenes 
4549 GeneSigDB 11.91186233 
cell cycle: g1/s check point 53 BioCarta 9.84279867 
Bladder cancer 89 KEGG 7.885181064 
Drug metabolism - cytochrome P450 94 KEGG 7.837851592 
Metabolism of xenobiotics by cytochrome P450 103 KEGG 7.837805455 
hsa-miR-21 34 miRecords 7.001844224 
KEGG_PATHWAYS_IN_CANCER 328 MsigDB 6.792625895 
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3.4 Conclusions  
We developed PAGED, an online database that provides the most comprehensive public 
compilation of gene sets. In the current release, PAGED contains a total of 25,242 gene 
sets, 61,413 genes, 20 organisms, and 1,275,560 records from five major categories: the 
pathway data from HPD, genome-level disease data from OMIM and GAD, 
transcriptome-level gene signatures from MSigDB and GeneSigDB, the post-
transcriptome microRNA data from miRecords, and proteome-level data from HAPPI. 
The number of overlapping genes between each data source, gene-set scale distribution, 
and case study in colorectal cancer shows the synergistic effect of integrating data 
 
Figure 3-5. CRC-specific gene-set association network (GSAN) with differential 
gene-set expressions.  
The differential gene expressions are from the differential analysis based on the 
microarray data, GSE8671. Node size: Gene-set scale (Counting genes in each gene 
set); Node color: Differential gene-set expression (NORM_ABS_FC); Node line 
color: Gene-set data source; and Edge width: Similarity score (≥ 0.1). 
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sources, which greatly facilitate access to gene-set-based prior knowledge. The current 
PAGED software can help users address a wide range of gene-set-related questions in 
human disease biology studies. 
 
In the future, one could improve gene-set similarity algorithms by using a global PPI 
network to calculate their distance. This would provide a more robust measurement for 
web interface development. A disease browsing function based on disease ontology and a 
network visualization function to show the gene-set association dynamically could also 
be added. The final goal is to perform multi-scale network modeling for molecular 
phenotype discoveries by integrating differential expressions with pathway and network 
topologies. The current release of PAGED provides a solid foundation for us to develop 
third-generation pathway analysis tools (27). 
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Chapter 4. Biomarker discovery with Network Expansion and Pathway 
Enrichment Analysis  
This section is based on the published work at (51). JYC guided the research team by 
providing ideas and feedback along the way, and revised the manuscript. HH analyzed 
the microarray dataset, generated the protein interaction network, ranked the disease 
proteins, and wrote the manuscript. XW conducted the pathway analysis and wrote the 
manuscript. TW and SDL helped analyze the result. RP helped maintain the database. CR 
helped curate the disease genes. 
4.1 Introduction 
Microarrays make possible the discovery of new functions and pathways of known genes, 
as they measure all the transcriptional activity in a biological sample (87). This high-
throughput procedure can be used in medical diagnostics, in biomarker discovery, and in 
investigating the ways a drug, disease, polymorphism or environmental condition affects 
gene expression and function (88, 89). However, one challenge has arisen because 
microarray technology generates a large amount of transcriptional data, which is hard to 
interpret for the results to gain insights into biological mechanisms (90). As a result, 
researchers have sought to analyze microarray data through the use of modern 
computational tools and statistical methods. 
 
In many cases, crucial genes show relatively slight changes, and many genes selected 
from differential analysis between groups of samples (e.g. normal vs. disease) by 
measuring the expression level statistically are also poorly annotated (88). From a 
biological perspective, functionally related genes often display a coordinated expression 
to accomplish their roles in the cell (91). Hence, to translate such lists of differentially 
expressed genes into a functional profile able to understand the underlying biological 
phenomena, one approach to aid interpretation is to look for changes in a group of genes  
with a common function (88). 
 
Gene set enrichment analysis (GSEA) is one of the most widely used methods for 
identifying both statistically and biologically significant genes from high-throughput data 
such as gene-expression assays (90). GSEA relies on pre-defined gene sets, while neglect 
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gene/protein interaction, pathway upstream or downstream information. Furthermore, 
GSEA still assumes that more differentially expressed genes are more crucial to the 
biology, which is not always true (65). Currently, gene expression signature analysis and 
pathway analysis remain two separate processes. 
 
From a view of network biology (92), cancer genes and proteins do not function in 
isolation; instead, they work in interconnected pathways and molecular networks at 
multiple levels (93), one study re-characterized them in a molecular interaction network 
for BRCA, and identified HMMR as a new susceptibility locus (94). Another study 
integrated protein interaction network and gene expression data to improve the prediction 
of BRCA metastasis (95). These works suggest that protein interaction networks and 
pathways, although noisy, incomplete and static, can serve as a molecular-level 
conceptual roadmap to guide future microarray analysis (7). 
 
In this work, we present an innovative approach - network expansion and pathway 
enrichment analysis (NEPEA) for integrative microarray analysis. We assume that 
organized knowledge will help microarray data analysis in significant ways, and the 
organized knowledge could be represented as molecular interaction networks or 
biological pathways. Based on this hypothesis, we develop the NEPEA framework based 
on network expansion (96) from the human annotated and predicted protein interaction 
(HAPPI) database (80), and pathway enrichment from the human pathway database 
(HPD) (28). 
 
We use a recently-published microarray dataset (GSE24215) related to insulin resistance 
and type 2 diabetes (T2D) as case study, since this study provided a thorough 
experimental validation for both genes and pathways identified computationally from 
classical microarray analysis and pathway analysis (97). In this study, skeletal muscle 
samples were collected in all participants (n = 20) in both the basal and insulin-stimulated 
state before and after bed rest. We perform the NEPEA analysis for this dataset based on 
the results from the classical microarray analysis to identify biologically significant genes 
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and pathways. Our findings are not only consistent with the original findings mostly, but 
also obtained more supports from other literatures. 
4.2 Methods 
The NEPEA method has three main components: 1) classical microarray analysis for data 
preprocessing consisting of quality control, normalization and differential analysis, 2) 
network expansion analysis for significant gene identification consisting of disease gene 
curation, network construction and significance score calculation, and 3) pathway 
enrichment analysis consisting of pathway search, pathway differential analysis and 
ranking. Using the microarray dataset - GSE24215 as an example, we introduce the 
detailed steps below: 
i. Microarray data preprocessing 
Quality Control 
We use AffyQCReport (applicable for Affymetrix platform) and ArrayQualityMetrics 
(applicable for Agilent platform) packages in Bioconductor to generate three plots to 
detect bad chips for each microarray dataset as: 1) examine a heat map that shows array-
array Spearman rank correlation coefficients. The map enabled us to plot outliers, failed 
hybridizations, and mis-tracked samples; 2) make a box plot of all perfect match 
intensities. The plot enabled us to detect outliers in terms of average intensity; and 3) 
make a distribution plot of kernel density estimates for perfect match intensities, which 
enables us to detect outliers in terms of shaped density. After applying 
ArrayQualityMetrics packages into quality control for microarray dataset - GSE24215, 
total 3 suspects out of 48 samples are flagged, which are kicked off as bad chips. 
 
Normalization 
We use Quantile normalization to normalize all the four qualified microarray datasets; 
MAS5 for Affymetric platform and normexp for Agilent platform on background 
correction. We also perform the steps background correction, normalization, probe 
speciﬁc correction, and summary value computation as following: 1) bgcorrect.method: 
mas; 2) normalize.method:quantiles; 3) pmcorrect.method:pmonly; and 4) 
summary.method:mas. 
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Differential analysis 
We use Limma (Linear Models for Microarray Data) package (98) in Bioconductor to 
identify differentially-expressed genes for each clinical group comparison from the 
qualified and normalized microarray datasets as 1) The package Limma uses an approach 
called linear models to analyze designed microarray experiments; 2) For statistical 
analysis and assessing deferential expression, Limma uses an empirical Bayes method for 
more stable inference and improved power, especially for experiments with small 
numbers of arrays; and 3) Differential genes are obtained by using the filters with p-
Value <= 0.05, Fold Change (FC) >= 1.3, and Average Expression Level (AEL) >= 40% 
after applying Limma package in Bioconductor. Average expression levels (AEL>=40%) 
have been checked to ensure the presences of the differential genes in the tissue - muscle. 
Duplicated genes with lower fold changes are eliminated, which implies that only the 
highest fold change for one gene will be kept. For microarray dataset - GSE24215, we get 
495 differential genes from insulin before-bed (IBB) group, and 930 differential genes 
from insulin after-bed (IAB) group 
ii. Network expansion analysis 
Disease gene curation 
The network expansion analysis is knowledge-guided approach, which relies on the 
disease-associated genes. Here we use T2D as an example to demonstrate how to curate 
disease-associated genes, but our method can be applied to any other disease phenotypes.  
We curate T2D-associated genes from OMIM (http://www.ncbi.nlm.nih.gov/omim) 
manually, evaluates them semi-automatically through searching in PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed/) as following: 1) Query: ("Type II Diabetes"[All 
Fields] OR "Type 2 Diabetes"[All Fields]) AND (prefix star[prop] OR prefix plus[prop]); 
2) Results: Records (Entries) -> Genes (Gene Symbol) -> Proteins (Uniprot ID); 3) 
GENE: Gene name, linked to GeneCards.org; 4) UNIPROT: Uniprot ID, linked to 
UniProt.org; 5) PUBMED: Count number of references where both term ("Type II 
Diabetes" OR "Type 2 Diabetes")  AND "GENE" appeared in PubMed, linked to 
PubMed; and 6) Obtain interactions from HAPPI 1.31 for these T2D-associated genes 
(seed genes) curated from OMIM. 
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Network reconstruction 
We construct a T2D-specific protein-protein interaction (PPI) network by using Oracle 
SQL Developer with high-quality interaction data in HAPPI version 1.31 and map 
differentially-expressed genes onto the T2D-specific PPI network by using Cytoscape as 
following: 1) Expand 39 seed genes (PUBMED >=50) in HAPPI 1.31 (4-Star, h-
Score >=0.75), and obtain 702 genes (including 32 seed genes); 2) The left 7 seed genes 
are also added into the network in order to show their expressions; and 3) Construct a 
T2D-specific PPI network with 709 nodes and 944 edges, by using Nearest Neighbor 
Expansion (NNE) approach (96). 
 
Significant gene identification 
We measure and rank all the differential genes in a T2D-specific protein-protein 
interaction (PPI) network by considering both differential expressions and network 
properties.  Differential genes are obtained by applying filters with p-Value <= 0.05, 
Average Expression Level (AEL) >= 40%, and Absolute Fold Change (ABS_FC) >= 1.3. 
Duplicated genes with lower fold changes have been eliminated, which implies that only 
the highest fold change for one gene will be kept. The T2D-specific PPI network is 
reconstructed by expanding all the seed genes curated from OMIM (PUBMED >=0), in 
HAPPI_1.31 (3-Star) (Confidence: h-Score >=0.45) 
We define Gene Significance Score (integrating both gene expression fold change - FC 
and network connectivity - NC) here as: 
Sig_Score =         
                 , |FC| = ABS_FC, absolute fold 
change. 
Constant parameters α1 and α2 here are for the balance between differential expressions 
and network properties. α1=3 and α2=1 are chosen since this pair can rank known disease 
genes on the top. Network connectivity (for un-weighted networks) NC: Weight_1 = 
Number of direct neighbors for each node. Network connectivity (for weighted networks) 
NC: Weight_2 = Sum of connection strength values on all neighbored edges. In the 
implementation, we use Weight_2 here. Connection strength here is the confidence for an 
interaction: h-Score. 
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iii. Pathway enrichment analysis 
Pathway search 
We search curated T2D-associated genes by using Oracle SQL Developer with 
comprehensive integrated pathway data in HPD version 2.1 (including pathway data from 
NCI-Nature curated, KEGG, BioCarta, and Protein Lounge), and map differentially-
expressed genes onto the pathways obtained. We obtain 92 pathways with 
(HITS/Pathway Scale) >= 3.5% AND HITS >=2 by querying 39 seed genes 
(PUBMED >=50) in HPD 2.1. 
 
Pathway differential analysis 
We provide average differential gene expressions in a pathway as: 
AVG_ABS_FC: The average of ABS_FC of all the available differential gene 
expressions in a pathway. 
We define pathway differential expressions here as: 
NORM_ABS_FC: The p*-norm of ABS_FC of all the available differential gene 
expressions in a pathway 
Usually, p-norm =       
      
 
           
      
For unification, we modify it as p*-norm =  
 
 
     
      
 
           
      
In the implementation, p = 6 have best performance to emphasize highly 
differential expressions in a pathway. 
We also provide maximal differential gene expressions in a pathway as: 
MAX_ABS_FC: The maximum value of ABS_FC of all the available differential 
gene expressions in a pathway; 
and count number of differentially expressed genes as: 
CNT_DIFF: Count number of differentially expressed genes (FC >= 1.3 AND p-
Value <= 0.05) in a pathway. 
We rank all the pathways by their pathway differential expressions - NORM_ABS_FC 
defined above. 
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4.3 Results 
i. Findings on insulin before-bed (IBB) group 
Top-20 differential genes 
Totally 495 differential genes are obtained, which are differentially-expressed in Insulin 
Before Bed (IBB) Group from the microarray dataset – GSE24215. Differential genes are 
obtained by using filters with p-Value <= 0.05, Fold Change (FC) >= 1.3, and Average 
Expression Level (AEL) >= 40% after applying Limma package in Bioconductor. 
Average expression levels (AEL>=40%) have been checked to ensure the presences of 
the differential genes in the tissue - muscle. Duplicated genes with lower fold changes are 
eliminated, which implies that only the highest fold change for one gene will be kept. 
Top-20 differential genes in IBB from GSE24215, ordered by absolute fold change 
(ABS_FC), are listed in Table 4-1. 
 
Table 4-1. Top-20 differential genes in IBB from GSE24215, ordered by FC 
(FC>=1.3, p-value <=0.05 and AEL >=40% after applying Limma package in 
Bioconductor). Note: Gene names are linked to GeneCards.org, UniProt IDs are linked to 
UniProt.org, and Evidences are linked to PubMed. 
Gene Symbol p-Value FDR Log2_FC ABS_FC Evidences 
SOCS3 0.00193 0.08858 2.54455 5.83426 28 
PDK4 0.00000 0.00074 -2.34193 5.06980 16 
THBD 0.00001 0.00243 2.25714 4.78043 0  
CISH 0.00013 0.01380 2.19425 4.57651 0  
G0S2 0.00000 0.00003 2.05403 4.15264 0  
MYC 0.00064 0.04234 1.97513 3.93164 23 
PDE4B 0.00000 0.00042 1.82895 3.55280 0  
ADAMTS4 0.00061 0.04111 1.76371 3.39569 1  
GADD45A 0.00002 0.00373 1.76132 3.39008 0  
RGS16 0.00217 0.09630 1.72508 3.30598 1  
EGR1  0.01342 0.29638 1.71863 3.29125 3  
HES1  0.00000 0.00012 1.71837 3.29065 1  
CCL2  0.00019 0.01796 1.71466 3.28219 111 
KLF15 0.00000 0.00000 -1.66849 3.17882 3  
PYCR1  0.00000 0.00000 1.66356 3.16797 0  
CITED2 0.00000 0.00000 -1.65106 3.14064 0  
OTUD1  0.00006 0.00778 -1.56650 2.96186 0  
ARRDC4  0.00000 0.00000 1.51143 2.85092 0  
NR1D1  0.00000 0.00003 -1.50730 2.84277 1  
PIK3R1 0.00000 0.00000 1.50274 2.83379 9  
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Top-20 significant genes 
Totally 130 significant genes in IBB from GSE24215 are obtained from all the 
differential genes in a T2D-specific protein-protein interaction (PPI) network, measured 
by using significant score (considering both differential expressions and network 
properties). The T2D-specific PPI network is reconstructed by expanding all the seed 
genes curated from OMIM (PubMed >=0), in HAPPI_1.31 (3-Star) (Confidence: h-
Score >=0.45). Top-20 significant genes in IBB from GSE24215, ordered by significant 
score (Sig_Score), are listed in Table 4-2. 
 
Table 4-2. Top-20 significant genes in IBB from GSE24215, ordered by Sig_Score, 
which is measured in the T2D-specific PPI network  
(PubMed >=0, h-Score >=0.45) for all the differential genes (FC>=1.3, p-value <=0.05 
and AEL >=40% after applying Limma package in Bioconductor) in IBB from 
GSE24215. 
Gene  p-Value FDR FC ABS_FC Weight_1 Weight_2 Score Evidence 
CCL2  0.00019 0.01796 1.71466 3.28219 98 75.2645 29.48048 111 
IL6 0.00164 0.08069 0.96338 1.94987 140 112.808 27.07169 52 
AKT2 0.00133 0.06955 -0.83609 1.7852 104 66.6378 23.32247 21 
IRS2  0.00011 0.01276 -0.78851 1.72729 60 49.3156 21.4162 124 
VEGFA  0.01432 0.30888 0.52022 1.43417 57 44.6818 19.40888 28 
PIK3R1 0 0 1.50274 2.83379 13 11.8228 16.57294 9  
MYC 0.00064 0.04234 1.97513 3.93164 10 8.8236 16.39929 23 
UCP3 0.00001 0.00147 -1.04039 2.05679 22 15.2626 16.25647 45 
SOCS3 0.00193 0.08858 2.54455 5.83426 7 6.3574 15.96385 28 
UCP2 0 0.00093 -0.80665 1.74915 22 15.7096 15.46493 78 
SCARB1 0.00115 0.06287 -0.38842 1.30896 30 19.9446 14.87011 11 
HSD11B1 0.01673 0.33975 -0.46192 1.37737 24 17.478 14.56683 20 
SORBS1 0 0 -1.13404 2.19472 13 10.08 14.34464 2 
KLF11 0 0.00001 -0.5958 1.51131 20 14.1964 14.11588 8 
AQP7 0.00023 0.02066 -0.71786 1.64474 9 7.305 11.35427 8 
RRAD 0.00018 0.01748 1.45449 2.7406 7 4.8134 11.31166 8 
LPIN1 0.00898 0.23354 -0.49106 1.40548 13 7.849 10.98119 9 
SMAD3 0.01644 0.33728 0.4402 1.35679 9 8.1113 10.96617 7 
ICAM1 0.00219 0.09689 0.74517 1.67617 8 6.539 10.91482 4 
TNFRSF1A 0.00039 0.02999 0.5936 1.509 8 6.6686 10.56144 0 
 
A T2D-significant protein-protein interaction (PPI) network (See Figure 4-1) is 
reconstructed by connecting Top-20 significant genes in IBB from GSE24215, with and 
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within the T2D-associated genes (seed genes) curated from OMIM (PubMed >= 50), in 
HAPPI_1.31 (3-Star) (Confidence: h-Score >=0.75) 
 
Figure 4-1. Top-20 significant genes in IBB from GSE24215, interacted with T2D-
associated genes.  
Node size represents Evidence for each gene, node color represents Log2_FC, red color 
implies over-expressed and blue color implies under-expressed. Green circled nodes are 
seed genes (T2D-associated genes curated from OMIM). Edge color represents 
Confidence (h-Score) for each interaction. Note: this figure was generated by Dr. Wu and 
used here with his permission. For details, please refer to (51).  
 
Top-20 significant pathways 
Totally 51 significant pathways (p*-norm >= 1.2) in IBB from GSE24215 are obtained 
from all the differential pathways, measured by using pathway differential expressions 
(p*-norm). Top-20 significant pathways in IBB from GSE24215, ordered by pathway 
differential expressions (p*-norm), are listed in Table 4-3. 
 
Table 4-3. Top-20 significant pathways in IBB from GSE24215 
They are ordered by pathway differential expressions (p*-norm), which is measured 
with all the available differential gene expressions in IBB from GSE24215. 
PATHWAY_NAME DB_SOURCE_ID NORM_ABS_FC MAX_ABS_FC 
IL-9 Pathway KEGG 2.56782 3.97011 
IL-10 Pathway KEGG 2.35238 3.97011 
IL23-mediated signaling events NCI-Nature Curated 2.29305 3.97011 
EPO signaling pathway NCI-Nature Curated 2.24041 3.97011 
Murine MSP-STK Signaling  KEGG 2.20505 3.28219 
IL6-mediated signaling events NCI-Nature Curated 2.19750 3.97011 
Type II diabetes mellitus KEGG 2.16107 3.97011 
Signaling events mediated by PTP1B NCI-Nature Curated 2.13761 3.97011 
growth hormone signaling pathway BioCarta 2.09285 3.31174 
IL-4 Pathway  KEGG 2.08410 3.97011 
Growth Hormone Signaling KEGG 2.06889 3.97011 
LDL Oxidation in Atherogenesis  KEGG 2.05923 3.28219 
IL4-mediated signaling events NCI-Nature Curated 2.02714 3.97011 
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Adipocytokine signaling pathway KEGG 1.97685 3.97011 
FoxO family signaling NCI-Nature Curated 1.97503 3.39008 
C. pneumoniae Infection in 
Atherosclerosis 
KEGG 1.89211 3.28219 
Calcineurin-regulated NFAT-dependent 
transcription in lymphocytes 
NCI-Nature Curated 1.87618 3.29125 
Jak-STAT signaling pathway KEGG 1.85834 3.97011 
MSP-RON Signaling  KEGG 1.84756 3.28219 
Insulin signaling pathway KEGG 1.80963 3.97011 
 
ii. Findings on insulin after-bed (IAB) group 
Top-20 differential genes 
Totally 930 differential genes are obtained, which are differentially-expressed After Bed 
(IAB) Group from the microarray dataset – GSE24215. Differential genes are obtained 
by using filters with p-Value <= 0.05, Fold Change (FC) >= 1.3, and Average Expression 
Level (AEL) >= 40% after applying Limma package in Bioconductor. Average 
expression levels (AEL>=40%) have been checked to ensure the presences of the 
differential genes in the tissue - muscle. Duplicated genes with lower fold changes are 
eliminated, which implies that only the highest fold change for one gene will be kept. 
Top-20 differential genes in IAB from GSE24215, ordered by absolute fold change 
(ABS_FC), are listed in Table 4-4. 
 
Table 4-4. Top-20 differential genes in IAB from GSE24215 
They are ordered by FC, (FC>=1.3, p-value <=0.05 and AEL >=40% after applying 
Limma package in Bioconductor). Note: Gene names are linked to GeneCards.org, 
UniProt IDs are linked to UniProt.org, and Evidences are linked to PubMed. 
Gene Symbol p-Value FDR Log2_FC ABS_FC Evidences 
NR4A3  0.00000 0.00000 4.18431 18.18032 2  
SOCS3 0.00005 0.00780 4.12982 17.50651 28 
GADD45B 0.00054 0.03440 3.56927 11.87016 1  
THBD 0.00000 0.00100 3.48248 11.17714 0  
ADAMTS4 0.00019 0.01838 3.40269 10.57580 1  
PDE4B 0.00000 0.00005 3.33522 10.09258 0  
FOS 0.00031 0.02436 3.31416 9.94630 18 
EGR1  0.00002 0.00362 3.11271 8.65008 3  
JUNB 0.00004 0.00743 3.08829 8.50488 2  
RGS16 0.00044 0.03038 2.96393 7.80246 1  
ZFP36  0.00012 0.01425 2.92543 7.59700 2  
MYC 0.00026 0.02179 2.86543 7.28754 23 
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CISH 0.00000 0.00049 2.78449 6.88992 0  
CCL2  0.00013 0.01462 2.59339 6.03513 111 
CXCL2  0.00006 0.00858 2.35828 5.12758 2  
ATF3  0.00202 0.07254 2.31257 4.96766 9  
SERPINA3  0.00732 0.14867 2.16589 4.48742 0  
NFIL3  0.00002 0.00434 2.15060 4.44013 0  
GADD45A 0.00382 0.10196 2.14953 4.43682 0  
IL6 2.0786 0.00044 0.03051 4.22398 52 
 
Top-20 significant genes 
Totally 237 significant genes in IAB from GSE24215 are obtained from all the 
differential genes in a T2D-specific protein-protein interaction (PPI) network, measured 
by using significant score (considering both differential expressions and network 
properties). The T2D-specific PPI network is reconstructed by expanding all the seed 
genes curated from OMIM (PubMed >=0), in HAPPI_1.31 (3-Star) (Confidence: h-
Score >=0.45). Top-20 significant genes in IAB from GSE24215, ordered by significant 
score (Sig_Score), are listed in Table 4-5. 
 
Table 4-5. Top-20 significant genes in IAB from GSE24215. 
They are ordered by Sig_Score, which is measured in the T2D-specific PPI network 
(PubMed >=0, h-Score >=0.45) for all the differential genes (FC>=1.3, p-value <=0.05 
and AEL >=40% after applying Limma package in Bioconductor) in IAB from 
GSE24215. Note: Gene names are linked to GeneCards.org, UniProt IDs are linked to 
UniProt.org, and Evidences are linked to PubMed. 
Gene  p-Value FDR Log2_FC ABS_FC Weight1 Weight2 Score Evidence 
CCL2  0.00013 0.0146
2 
2.59339 6.03513 98 75.2645 34.9751 111 
IL6 0.00044 0.0305
1 
2.0786 4.22398 140 112.808 34.68919 52 
IRS1  0.00902 0.1649
4 
-0.68912 1.6123 103 83.1045 23.58864 280 
IL6R 0.00002 0.0040
4 
0.79678 1.73722 70 55.9728 22.14359 7  
VEGFA  0.00017 0.0172
4 
0.92831 1.90304 57 44.6818 21.6589 28 
APP 0.03329 0.3145
8 
-0.43503 1.35194 80 68.3971 21.01141 15 
SOCS3 0.00005 0.0078 4.12982 17.50651 7 6.3574 20.52815 28 
ADRB2 0.00016 0.0164 1.0105 2.01461 37 31.2254 20.09311 10 
FOXO1 0.00008 0.0105
6 
0.52622 1.44015 65 44.529 19.42493 59 
MYC 0.00026 0.0217
9 
2.86543 7.28754 10 8.8236 19.33394 23 
SOD2 0.00164 0.0647
8 
0.82246 1.76841 50 29.5486 18.85629 4 
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DGKD 0.02661 0.2823
8 
0.5992 1.51487 42 34.932 18.59775 2 
FOS 0.00031 0.0243
6 
3.31416 9.9463 7 6.3552 18.17698 18 
PIK3R1 0 0.0000
8 
1.67218 3.18695 13 11.8228 17.1966 9 
XBP1 0.00338 0.0960
6 
0.40352 1.32273 42 26.9454 16.35234 9 
AGT 0.00295 0.0885
2 
0.59516 1.51064 24 18.032 15.28071 42 
UCP3 0.00163 0.0644
9 
-0.75312 1.68543 22 15.2626 15.10061 45 
UCP2 0.00186 0.0689
7 
-0.60181 1.51762 22 15.7096 14.63273 78 
PPARGC1
A 
0.00479 0.117 0.53018 1.44411 17 13.6 13.65437 111 
GFPT2 0.04473 0.3627
4 
0.54879 1.46286 14 12.2852 13.2432 2 
 
A T2D-significant protein-protein interaction (PPI) network (See Figure 4-2) is 
reconstructed a by connecting Top-20 significant genes in IAB from GSE24215, with and 
within the T2D-associated genes (seed genes) curated from OMIM (PubMed >= 50), in 
HAPPI_1.31 (3-Star) (Confidence: h-Score >=0.75) 
 
Figure 4-2. Top-20 significant genes in IAB from GSE24215, interacted with T2D-
associated genes.  
Node size represents Evidence for each gene, node color represents Log2_FC, red color 
implies over-expressed and blue color implies under-expressed. Green circled nodes are 
seed genes (T2D-associated genes curated from OMIM). Edge color represents 
Confidence (h-Score) for each interaction. 
 
Top-20 significant pathways 
Totally 64 significant pathways (p*-norm >= 1.2) in IAB from GSE24215 are obtained 
from all the differential pathways, measured by using pathway differential expressions 
(p*-norm). Top-20 significant pathways in IAB from GSE24215, ordered by pathway 
differential expressions (p*-norm), are listed in Table 4-6. 
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Table 4-6. Top-20 significant pathways in IAB from GSE24215. 
They are ordered by pathway differential expressions (p*-norm), which is measured with 
all the available differential gene expressions in IAB from GSE24215. 
PATHWAY_NAME DB_SOURCE_ID NORM_ABS_FC MAX_ABS_FC 
IL-9 Pathway KEGG 6.70137 10.92515 
IL-10 Pathway KEGG 6.43693 10.92515 
IL6-mediated signaling events NCI-Nature Curated 6.34297 10.92515 
EPO signaling pathway NCI-Nature Curated 6.13163 10.92515 
IL23-mediated signaling events NCI-Nature Curated 6.01717 10.92515 
igf-1 signaling pathway BioCarta 5.98831 9.94630 
Type II diabetes mellitus KEGG 5.90782 10.92515 
Signaling events mediated by PTP1B NCI-Nature Curated 5.83706 10.92515 
IL-4 Pathway  KEGG 5.71129 10.92515 
signal transduction through il1r BioCarta 5.68010 9.94630 
Growth Hormone Signaling KEGG 5.67342 10.92515 
Calcineurin-regulated NFAT-dependent 
transcription in lymphocytes 
NCI-Nature Curated 5.66004 9.94630 
IL4-mediated signaling events NCI-Nature Curated 5.53802 10.92515 
FOXM1 transcription factor network NCI-Nature Curated 5.44978 9.94630 
Adipocytokine signaling pathway KEGG 5.40776 10.92515 
GDNF-Family Ligands and Receptor 
Interactions 
KEGG 5.18210 9.94630 
HIF-1-alpha transcription factor network NCI-Nature Curated 4.99991 9.94630 
Regulation of nuclear SMAD2/3 signaling NCI-Nature Curated 4.91493 9.94630 
Insulin signaling pathway KEGG 4.89924 10.92515 
Jak-STAT signaling pathway KEGG 4.80603 10.92515 
 
4.4 Conclusions 
In this work, we apply both classical microarray analysis (such as differential analysis in 
Bioconductor) and the knowledge-guided analysis (network expansion analysis and 
pathway enrichment analysis). From the evidence from literature (PubMed), Top 20 
significant genes from our analysis have more supports than Top 20 differential genes 
from simple differential analysis, in the case study on the microarray dataset - GSE24215. 
This implies the vitality of our hypothesis on which organized knowledge will help 
microarray data analysis in significant ways. 
 
For GSE24215 dataset, both of the two networks (shown in Figure 1 and Figure 2) 
consist of two subnetworks. The bigger one includes genes that are highly related to 
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diabetic type 2.  Some of genes are shared between before bed network and after bed 
network, like insulin receptor, peroxisome proliferator-activated receptor gamma and so 
on. For those shared genes, their expressions are different between these two conditions. 
We can see from the figure that IRS1, PPARG are under-expressed in after bed condition 
while IRS2 are under-expressed in before bed condition. Beside those shared molecules, 
some only show in after bed condition, like PPARGC1A, IDE, IL6R, APP, and PTPN1 
while others only show in before bed condition, like CD36, SCARB1, SELP, ICAM1, 
TNFRSF1A, HSD11B1, and AKT2. The smaller one is relatively small sub-network. 
Commonly shared gene between before bed and after bed are HNF1A, HNF4A and MYC 
with similar expression level.  Some genes like TCF7L2 only show up in before bed 
network while GCK, GFPT2, FOXO1, and SIRT1 only show in after bed network. 
 
Another interesting finding is that the molecules which connect the red sub-network and 
blue-subnetwork are different. In before bed network, SMAD3 play this important role 
while in after bed network it is FOS that connect these two subnetworks. In fact, FOS and 
SMAD3 are physically interacting with each other and together Smad3 cooperates with c-
Jun/c-Fos to mediate TGF-beta-induced transcription. Finally though IGF1 doesn’t show 
up in the network, yet the IGF1 pathway is highly ranked (refer to pathway analysis part) 
in the after bed condition. 
 
The key finding on GSE24215 was that bed rest was associated with a paradoxically 
increased response to insulin of genes involved in acute-phase response and inflammation, 
including IL-6 signaling, IL-10 signaling, and the ER stress pathway, contrasting the 
development of severe peripheral insulin resistance of glucose metabolism in young 
healthy men. The present study demonstrated that 9 days of bed rest induces severe 
transcriptional changes of genes potentially involved in the pathogenesis of insulin 
resistance and T2D in skeletal muscle, which might to some extent explain the harmful 
effect of a sedentary lifestyle on human metabolism. Impaired expression of HK2, 
VEGFA, NDUFB6, PPARGC1A, and OXPHOS genes in general, as well as a markedly 
increased expression of RRAD, are among the prime candidates contributing to the 
development of insulin resistance during bed rest. 
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Our analysis on this microarray dataset also shows that Insulin-stimulation After Bed-rest 
(IAB) is associated with the same significant genes: VEGFA (Rank: 5), PPARGC1A 
(Rank: 19), HK2 (Rank: 23), and RRAD (Rank: 29). We also found IAB is associated the 
same/similar pathways: IL-10 Pathway (Rank: 2) from KEGG database, IL6-mediated 
signaling events (Rank: 3) from NCI-Nature Curated pathway database, igf-1 signaling 
pathway (Rank: 6)from BioCarta database, Type II diabetes mellitus (Rank: 7) from 
KEGG database, Growth Hormone Signaling (Rank: 11) from KEGG database, Insulin 
signaling pathway (Rank: 19) from KEGG database, Jak-STAT signaling pathway (Rank: 
20) from KEGG database, il 6 signaling pathway (Rank: 27) from BioCarta database, and 
role of erbb2 in signal transduction and oncology (Rank 31) from BioCarta database. 
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Chapter 5. Drug Repositioning using Literature Mining: Computational 
Connectivity Map 
This section is based on the published work at (52). JYC conceived this work, guided the 
research team by providing ideas and feedback along the way, and revised the manuscript. 
HH involved the drug efficacy evaluation hypothesis development, carried out annotation 
web page development, designed the case studies and wrote the manuscript. XW 
participated in the drug efficacy hypothesis initiation, directionality concept development, 
case studies and manuscript writing. RP updated the PubMed database and tables in the 
Apex application. JL developed the previous version of C2Maps and performed case 
studies about the web server in her paper. GZ helped with annotation web page 
development.SI performed the directionality curations for breast cancer and colorectal 
cancer.  
5.1 Introduction 
Screening millions of chemical compounds to identify “hit” compounds for specific 
disease gene/protein targets has been a mainstream paradigm for modern drug 
discovery(99). While the conventional “One disease, One gene, and One drug” paradigm 
(9)works effectively for simple genetic disorders, it fails to produce effective drugs for 
complex diseases such as cancer (10). In complex diseases, many genes may be 
contributing to the disease’s phenotype; therefore, identifying a “magic bullet” drug 
compound can be quite elusive. 
 
Polypharmacology, which focuses on multi-target drugs, has become a new paradigm in 
drug discovery. Polypharmacology drugs have conventionally been viewed to have 
undesirable ‘promiscuity’. However, recent research studies show, in the case of both 
older psychiatric drugs and modern anticancer therapies, that this promiscuity is intrinsic 
to the drug’s therapeutic efficacy(11). Although there are over 40 drug-target (protein-
compound interaction) databases according to Pathguide(100), (e.g. DrugBank(101), 
STITCH(102), CTT (103), CTD (104)and BindingDB(105), etal), a disease-specific 
searching platform is still needed to fully understand drug effects on the human body. 
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A new cancer systems biology approach to drug discovery has emerged in recent years. 
The primary focus of this paradigm is to understand the actions of drugs by considering 
targets in the context of the biological networks. By focusing on a systems level, it 
provides a better way to examine complicated diseases that can be caused by several gene 
mutations, such as cancer (106). However, most methods published so far focus on 
modeling the structure of the drug target network qualitatively (107). To examine a 
drug’s effect on a molecular network representative of the disease, more quantitative and 
accurate modeling techniques need to be developed by utilizing the concept of network 
pharmacology (106) or network medicine (13). 
 
In post-genome biology, molecular connectivity maps have been proposed to establish 
comprehensive knowledge links between molecules of interest in a given biological 
context (108).Molecular connectivity maps between drugs and genes/proteins in a 
disease-specific context can be particularly valuable because they allow researchers to 
evaluate drugs against each other using their unique gene/protein-drug association 
profiles. The functional approach to drug comparisons helps researchers gain global 
perspectives on both the toxicological profiles and therapeutic profiles of candidate drugs. 
Furthermore, the time it takes to develop high quality drugs in new therapeutic areas can 
also be reduced by using this method. 
 
One approach for developing molecular connectivity map data is to generate disease-
specific protein-drug association profiles computationally by mining bio molecular 
interaction networks and PubMed literature (24) . The Computational Connectivity Maps 
(C
2
Maps) web server (109) is an online bioinformatics resource that provides biologists 
with potential relationships between drugs and genes/proteins in specific disease contexts 
based on network mining and literature mining. It’s based on the concept of network 
pharmacology by examining many drugs at the same time and studying the drug disease 
relationship based on the underlying protein interaction network instead of drugs’ direct 
target. C
2
Maps provides quantitative measurements of protein’s and drug’s relevance to a 
specific disease by applying networking mining and the statistical testing methods in text 
mining and thus offers new insight to assess overall drug efficacy and toxicity. 
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Occurrences between proteins and drugs from literature mining of C
2
Maps don’t 
necessarily tell research what type of relationships they have, therapeutic or toxic. To 
overcome these limitations, we further standardize the classifications between proteins 
and drugs and then perform literature curations to determine drugs’ effect on proteins on 
higher resolutions. Such valuable information is not readily available from the existing 
drug-target (protein-compound interaction) databases (e.g. DrugBank, STITCH, CTT, et 
al.) they may be scattered within a description or referenced text. 
 
To assess drug pharmacological effect, such as drug efficacy and toxicity, we assume that 
“ideal” drugs for a patient diagnosed with a certain disease should modulate the gene 
expression profiles of this patient to the similar level with those in normal healthy people. 
Therefore, for those statistically over-expressed genes, drugs should be able to inhibit 
their expression level to the normal range. Similarly, for those statistically under-
expressed genes, drugs should be able to activate their expression level to the normal 
range. In this way, drugs can treat or prevent the disease through reversing the gene 
expression level from disease status to the normal range, thus modulating cellular 
function as in normal cells. 
 
By assuming that if the gene expression profiles of disease and drug are opposing, then 
the drug might be a potential treatment option of the disease, (108) identified novel drug 
indications in diet-induced obesity or Alzheimer's disease. Another work by Atul(17) 
utilized the same gene expression data and algorithms with large scale gene expression 
data from GEO to study associations between 100 diseases and 164 drug molecules. They 
found candidate therapeutics for 53 of the diseases. These studies are proof of principle 
that how using public genomics database and similar hypothesis can benefit drug 
discovery. Though gene expression data are publicly available for more than 1000 
compounds in the second release of (108), yet there are numerous compounds that are not 
part of the database. Another limitation of this overly simplified hypothesis lies in it 
doesn’t differentiate important genes from unimportant ones. Ideally a biological 
meaningful scoring methods needs developed.  
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Drugs effect data from literatures could be complementary here. In this work, we focus 
on building comprehensive disease-gene-drug connectivity relationships with drug-
protein directionality (inhibit/activate) information based on the C
2
Maps platform (109).  
To show the feasibility of applying the data for computational drug discovery, we took 
previous hypothesis a step forward by but assigning different weights to different genes. 
However this work aims to provide the data for the future network pharmacology 
research instead of developing a drug efficacy prediction method .This work has the 
following contributions: 
 
1) The C
2
Maps website itself has been not published before though (109) only provides 
the underlying computational methodology and relative low disease coverage such as 
Alzheimer’s Disease.   
2) We create an interactive interface for directionality annotation of drug-protein pairs 
with literature evidences from PubMed. 
3) We curate the directionality information of drug protein pairs for three disease 
phenotypes: breast cancer, colorectal cancer and Alzheimer disease from 5133, 4869 and 
3928 PubMed abstracts, respectively. We also upload these curated directionality 
information into the C
2
Maps, and perform a statistical analysis on them. Curation of 
additional diseases, like pancreatic cancer and autism, is still on-going.  
4) We enhance the functionality of disease-specific searching for relevant proteins and 
drugs with directionality information. 
5) We update the comprehensive disease-gene-drug connectivity data in the C
2
Maps 
databases, including 19,569,563 PubMed abstracts in the current version and 142,523 
unique 3 star protein interactions in the current version. 
6) We also use breast cancer as a case study to demonstrate the functionality of disease-
specific searching for relevant drug-protein pairs with directionality information. 
7) Based on the searching result, we show the feasibility of performing drug 
pharmacological effect evaluation for two important breast cancer drugs to show the 
power of updated C
2
Maps in drug efficacy and toxicity assessment. 
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5.2 Methods 
i. Data sources and systems design 
As shown in Figure 5-1, the C
2
Maps platform incorporates three major components in its 
systems design: 
 Network mining component takes a query disease term as the input, and generates 
a ranked list of disease-relevant proteins as the output, through 1) MeSH term 
matching, 2) disease-associated gene searching from OMIM (110),3) network 
expanding in HAPPI (80), and 4) network-based protein ranking; 
 Text mining component takes an input list of genes or proteins, and creates a list 
of enriched disease candidate drugs that are significantly associated with the 
disease-relevant proteins from the previous component as the output, through 1) 
gene/protein name mapping using UniProtKB, 2) article abstract retrieving from 
PubMed, 3) drug/chemical compound identification using MeSH term, and 4) 
disease-specific drug-protein pair ranking; 
 Drug effect annotating component can allow users to 1) retrieve disease-specific 
drug-protein association list, 2) curate drug-protein directionality information 
from PubMed abstract, 3) annotate these drug-protein directionality information 
interactively, and 4) browse disease-specific drug-protein directionality 
information online. 
 
In specific, we apply the network mining method originally developed by Chen et al.(60) 
to fish cancer relevant proteins from the protein interaction network. We expand cancer 
related genes/proteins using PPIs recorded in the Human Annotated and Predicted Protein 
Interactions (HAPPI) database to construct cancer-specific PPI sub-network. A protein’s 
cancer relevance score rp is calculated as the function (1).  
)),(ln()),(ln(    qpNgpconfkr NETqNETqp       (1) 
Here, p and q are indices for proteins in the cancer-related interaction network PPI, k is 
an empirical constant (k=2 in this study), conf(p, q) is the confidence score assigned to 
each interaction between protein p and q, and N(p, q) holds the value of 1 if the protein p 
interacts with q. 
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Figure 5-1. C2Map workflow for a given disease-specific study. 
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To retrieve the important drugs for cancers and to parse out drug terms in the articles, we 
acquire PubMed abstracts with the list of cancer-related genes/proteins derived earlier 
from PPI as queries. Drug term frequency is calculated and compared to term statistical 
distributions from the PubMed abstracts to get the p-value of drugs using function (2). 
Random
Randomj
NET
NETj
RandomjNETj
j
N
TdVar
N
TdVar
TddfTddf
)|()|(
))|()|((





(2) 
 
Here, ={ , , …}is generated by sampling the entire collection of retrieved 
abstracts . =| | is the size of each sample. ={ , …}refers to a random 
sample generated by randomly sampling the entire number of PubMed abstracts; the size 
of the random sample is . and refer to average document 
frequencies of in  and . and  refer to document frequency 
variances of  in  and in . A two-sided tails t-test was then performed to calculate 
the p-value. A thorough description of the computational components and algorithms 
used, along with data sets and data processing parameters, is described in detail by Li et 
al. (109). 
 
The C
2
Maps platform follows a multi-tier architecture design. The back end was 
implemented as PL/SQL packages in the Oracle 11g database server, with the Oracle 
Text engine enabled, to ensure scalable querying of PubMed text documents. The 
C
2
Maps application middleware was implemented in the Oracle Application Express 
(APEX) server, which bridged between the Apache web server and the Oracle database 
server. 
 
The current release of C
2
Maps uses the following data sets: 19,569,563 records in the 
PubMed/MEDLINE baseline database (111), 142,523 human protein-protein interactions 
above 3-star confidence ratings in the HAPPI database(80), 26,142 descriptors in the  
MeSH database (Category C for diseases and Category D for chemicals and drugs) (112), 
20,331 entries for the curated human proteins in the UniProtKB database (113), 18,344 
entities in the OMIM database (61), and 4,772 entities in the DrugBank. Current statistics 
for the included database records is also shown in Table 5-1. The top 500 drug-protein 
NETT  1NETT  2NETT 
NETT  NETN NETT  RandomT  1RandomT  2RandomT 
RandomN )|( NETj Tddf  )|( Randomj Tddf 
jd NETT  RandomT  )|( NETj TdVar  )|( Randomj TdVar 
jd NETT  RandomT 
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pairs for ‘Alzheimer disease’, ‘Breast cancer’ and ‘Colorectal cancer’ from C2Maps were 
manually curated by assigning the effects of drugs on proteins as defined in the next 
section. As a result, C
2
Maps platform contains 3928, 5133 and 4869 curated records for 
Alzheimer disease, Breast cancer and colorectal cancer respectively. All data is 
warehoused in a local Oracle 11g database.  
 
Table 5-1. Current statistics for the included database records 
Dataset Data Resource Record count 
Biomedical Literature PubMed 19,569,563 
Human Protein-Protein 
Interaction 
Unique HAPPI 3-star interactions 142,523 
Disease and Drug Terminology MeSH descriptors 26,142 
Human Protein UniProtKB 20,331 
Disease-Gene relationships OMIM 18,344 
Drug Information DrugBank 4,772 
 
ii. Drug effect annotation 
Since our hypothesis is that ideal drugs for a patient diagnosed with a certain disease 
should modulate the gene expression profile of this patient to the similar level with those 
in healthy people, we annotate a drug’s pharmacological effect on a protein using one of 
the following three categories (also illustrated in Figure 5-2):  
 
Figure 5-2  Illustration of drug pharmacological effects based on directionality 
information for drug-protein pairs 
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 Therapeutic: if the drug activates the under-expressed protein or inhibits the over-
expressed protein, we define that the drug has a therapeutic effect on that protein 
 Toxic: if the drug activates the over-expressed protein or inhibits the under-
expressed protein, we define that the drug has a toxic effect on that protein 
 Ambiguous: if there is missing directionality information for either the nodes (i.e. 
proteins/drugs) or edges. 
iii. Perturbation Effects of Drugs on Proteins/Genes 
We use breast cancer as an example to illustrate how we curate the directionality of a 
drug-protein pair retrieved from the C
2
Maps platform. The followings are four categories 
of an annotated drug-protein relationship pair (also, refer to Table 5-2): 
 Activation - “Subsequent injection of tamoxifen triggers the transient activation of 
Akt/PKB in mice.” (Tamoxifen and AKT1_HUMAN, PMID: 12640620). 
 Inhibition - “Treatment of cells with Cycloheximide (CHX) prevented the 
activation of p53 in all phases of the cell cycle and its accumulation in G1/S and 
S.” (P53_HUMAN and Cycloheximide, PMID:9484835). 
 Indirect Yes - “Hydroxyurea-mediated DNA synthesis arrest of S phase MCF7 
cells led to a loss of BRCA1 from these structures.” (BRCA1_HUMAN and 
Hydroxyurea, PMID:9267023). 
 Ambiguous - “GRalpha and GRbeta transcripts are coordinately upregulated in 
CEM-C7 cells and coordinately downregulated in IM-9 cells by dexamethasone.” 
(GCR_HUMAN and Dexamtheasone, PMID:12974663). 
 
Table 5-2. Curation of drug-protein relations from Pub-Med abstracts 
Relation Protein Drug PMID Relation Proof 
Up-Regulated BRCA1 Estradiol 7553629 
“BRCA1 mRNA and protein levels were 
significantly decreased in estrogen-depleted 
MCF-7 and BT20T cells and increased again 
after stimulation with beta-estradiol”. 
 
Down-
Regulated 
P53 Cycloheximide 9484835 
“Treatment of cells with cycloheximide 
(CHX) prevented the activation of p53 in all 
phases of the cell cycle and its accumulation 
in G1/S and S”. 
 
Indirect BRCA1 Hydroxyurea 9267023 
“Hydroxyurea-mediated DNA synthesis 
arrest of S phase MCF7 cells led to a loss of 
BRCA1 from these structures”. 
 
Ambiguous GCR Dexamethasone 12974633 “GRalpha and GRbeta transcripts are 
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coordinately upregulatedin CEM-C7 cells 
and coordinately downregulated in IM-9 cells 
by dexamethasone”. 
 
Unknown AKT1 Phosphothreonine 11087733 
The drug-protein relation is not mentioned in 
the text. 
 
We can see that the literature does contain such information and thus provides basis for 
the directionality information retrieval. We focus on curating drug actions in the disease 
context rather than only in cell lines like in (108). Different research works under specific 
contexts may produce conflicting conclusions regarding drug protein relationship. Take 
Tamoxifen and estrogen receptor as examples. As shown in Table 5-3, we successfully 
extracted 7 article abstracts which support the inhibitory effects of Tamoxifen on 
estrogen receptor and 2 PubMed abstracts which support the stimulatory effects of 
Tamoxifen on estrogen receptor. The pre-dominant evidence showing Tamoxifen’s 
inhibition on estrogen receptor (114) matches well with the fact that Tamoxifen acts as an 
antagonist for estrogen receptor. Beside checking the majority vote of all the related 
papers, the original references was also checked. For Tamoxifen, it inhibits estrogen 
receptor in the mammary tissue while activating estrogen receptor in bone density.  In the 
breast cancer case study, we decided Tamoxifen’s inhibiting effect on estrogen receptor 
since the gene expression experiment was based on breast tissue. In the future, one could 
add additional contexts such as experimental conditions, disease subtypes and so on. In 
the current version, they are not added due to limited availability of those data in 
abstracts. 
 
Table 5-3. PubMed evidence for Tamoxifen’s effect on ESR1 
Drug Protein PMID Direction 
Tamoxifen ESR1_HUMAN 14507640 -1 
Tamoxifen ESR1_HUMAN 2359140 -1 
Tamoxifen ESR1_HUMAN 14759988 -1 
Tamoxifen ESR1_HUMAN 11774281 -1 
Tamoxifen ESR1_HUMAN 2137212 -1 
Tamoxifen ESR1_HUMAN 9328205 -1 
Tamoxifen ESR1_HUMAN 11261829 -1 
Tamoxifen ESR1_HUMAN 12767276 1 
Tamoxifen ESR1_HUMAN 11812086 1 
1 represents that the drug up regulates the protein while -1 represents down regulation 
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iv. Data access and website usage 
The C
2
Maps online platform (http://bio.informatics.iupui.edu/cmaps) provides 
researchers a web-based bioinformatics user interface, following principles described in 
(115). As shown in Figure 5-3, users can begin with a single disease term as a query and 
navigate to extract significant subsets of the disease-specific C
2
Maps.  
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Figure 5-3. The navigational site map of the C2Map platform. 
The numbers refer to: 0. Configure search preference; 1. Input interest disease; 2. 
Generate Protein-Drug connectivity; 3. Refine initially constructed connectivity map; 
4. Link to protein page; 5. Link to drug page; 6. Link between protein and drug 
pages; 7. Link to evidence article pages; 8. Link to external data resources (MeSH, 
UniProt and PubMed); 9. Import enriched disease specific protein-drug associations 
for further annotation; 10; Authorized users (curators) set up profiles and login in; 11. 
Annotate effects of drugs on protein/genes; 12. Release annotation results; 13. 
Browse annotated disease-protein-drug connectivity relationships; 14. Filter or search 
for interested subset of connectivity relationships.  
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We also show snapshots of C
2
Maps output web pages in Figure 5-4, using “Breast 
Cancer” as a query example. The statistically significant relationships between proteins 
and drugs are extracted from the literature are displayed in tabular format (Figure 5-4).  
 
Figure 5-4. Web Interface for C2Maps basic query function. 
(a) C2Maps default home page with a query box; (b) Preference configuration page 
with editable parameters in network mining component and text mining component; 
(c) Disease-specific protein-drug connectivity map page shows disease-relevant 
proteins, their ranking score, and drugs, their p-value, their relative frequency, as well 
as evidences supporting the protein-drug associations; (d) Filter result page shows the 
subset of the connectivity map; (e) Protein detail page shows the disease-related 
protein, its partner proteins in interaction network, and related drugs in retrieved 
abstracts; (f) Drug detail page shows the disease-related drugs, its neighbor drugs in 
Medical Subject Heading Tree, and related proteins in disease-specific protein 
interaction network; (g) Article detail page shows the literature references in PubMed 
with protein entity and drug entity highlighted. The url is 
http://bio.informatics.iupui.edu/cmaps 
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The proteins, drugs, and evidence numbers are further linked to protein, drug, and the 
article detail page, respectively. The search results can also be sorted by the protein 
ranking score (R-Score) and Chemical/Drug significance (P-Value). In addition, the page 
also lists Disease Context (disease name of user interest) and Disease Terminology 
(disease name containing query term in the controlled vocabulary of Medical Subject 
Headings). Users can also specify advanced search criteria for further 
biological/pharmacological analysis. Annotations for the extracted relations could be 
performed from the ‘Annotate Data’ tab. 
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v. Browsing Disease-specific drug-protein relationship information  
Any public C
2
Maps database user can access the well curated drug-protein directionality 
data. The database will display disease, protein, drug directionality, and PudMed 
evidence for each record. Each column can be sorted or filtered. One can also display 
only drug-protein directionality belonging to certain disease by selecting it from the drop 
down list (Figure 5-5b). Furthermore, the user can also search the keywords, such as 
 
Figure 5-5. Web Interface for C2Map Annotation data browse.  
(a) Annotation Data: main search page allowing either public browse or authorized 
curation; (b) Annotation Data Browse: displaying curated directionality between drug 
and proteins for certain disease; (c) Filtering: Each column support filtering (e.g., 
only show ‘Down regulated’ directionality); (d). Search function:  search by either 
drug or protein. For example, search all records for ESR1 protein. The url is 
http://bio.informatics.iupui.edu/cmaps 
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protein name or drug name, to retrieve only specific records. Currently, the C
2
Maps 
platform contains 3928 curated records for Alzheimer disease, 5133 curated records for 
breast cancer, and 4869 curated records for colorectal cancer. More curation information 
will be updated regularly. 
vi. Interactive interface for directionality annotation 
An authorized C
2
Maps database user can also annotate selected C
2
Maps contents by 
performing manual curation from the ‘Annotate Data’ tab. The user may apply for an 
annotator’s account to edit protein-drug interactions suggested by the C2Maps automated 
recommendation system. This editing is provided through a separate user interface that 
enables the annotator to categorize protein-drug relationships as direct (including 
activation, inhibitory, ambiguous), indirect, or unknown (Figure 5-6f). The user will first 
select the assigned disease and the C
2
Maps webserver will populate disease relevant 
protein and drug pairs. All the PudMed abstracts mentioning both the relevant protein and 
drug will be pulled out and the curator can read the abstract to annotate the directionality 
between the drug and the protein. The user can also edit (Figure 5-6d) each record or 
delete it. 
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Figure 5-6. Web Interface for C2Map Annotation data curation. 
(a) Annotation Data: main search page allowing either public browse or authorized 
curation; (b) Curator login: require login to curate directionality for certain disease; 
(c) User sign up: application form to create an account as a curator; (d) Data Browse:  
the browse page after login; (e) Data Edit: update or delete previously curated 
records; (f) Data Entry:  1. select disease; 2. relevant protein based on 1; 3. relevant 
drug based on 2; 4. relevant PubMed ID based on both 2 and 3; 5. relevant abstract 
based on PubMed ID from 4; 6. Curate directionality based on 5. 
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5.3 Results 
i. Statistical analysis for reliability 
The major computational components of the C
2
Maps platform were developed using 
validated computational techniques. In the network mining component, protein 
interaction network expansion was able to reduce the initial biases and low data coverage, 
which may have existed in the seed list of protein. We used the new HAPPI database 
instead of other protein interaction databases because of its overall better data quality 
(comparable or better than data in the HPRD database for quality star grades of 3 and 
above) and coverage (more than 280,000 human protein interactions with star grades of 3 
and above), which was thoroughly described in Chen et al.(80). In the text mining 
component, the PubMed abstract retrieval for each protein was shown to improve 
Information Retrieval (IR) recall performance without sacrificing precision The quality of 
disease drug identifications was shown to outperform comparable systems with balanced 
sensitivity, specificity, and positive predictive values (for details, refer to Li et al. (109)).  
 
In Table 5-4, we show a summary of C
2
Maps platform performance, by comparing its 
overall sensitivity, specificity, PPV (positive predictive value), F-score, and ACC 
(accuracy) measures among a number of cancers. The result confirmed that C
2
Maps 
performed well consistently across different disease studies. 
 
Table 5-4.  Performance assessment of C2Maps in varying cancers. 
 
Bladder Breast Leukemia Lung Lymphoma Melanoma Ovary Pancreas Prostate 
Sensitivity 80.84% 79.80% 83.16% 78.44% 81.20% 77.39% 80.88% 84.99% 82.84% 
Specificity 87.11% 84.91% 86.11% 89.37% 87.60% 91.53% 84.34% 86.45% 88.38% 
ACC 86.70% 84.27% 85.63% 87.86% 86.78% 90.17% 84.09% 86.34% 87.93% 
PPV 30.51% 43.01% 53.39% 54.06% 48.92% 49.24% 28.84% 33.82% 38.88% 
F-Score 44.30% 55.89% 65.03% 64.01% 61.05% 60.19% 42.52% 48.38% 52.92% 
The experiment were performed using a protein interaction confidence minimum threshold of 3 
star and above (i.e., reliability score of >0.75) and retrieved drug p-value at a minimum threshold 
of 0.05. The detailed evaluation procedures and measurement definitions, they can be found in 
the “Method FAQ” page of the C2Maps website and as supplemental materials. The table was 
developed by Jiao Li and was used here by her permission (52).  
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ii. A case study on breast cancer specific searching for relevant drug-protein pairs 
with directionality information 
We evaluated breast cancer drugs from C
2
Maps based on our hypothesis. First, we 
obtained top 500 drug protein pairs for breast cancer from the C
2
Maps web server, 23 
drugs and 103 proteins, respectively. The rp scores for those proteins range from 1.69 to 
169.82 and the P-Values for those drugs are all below 0.05. Well known breast cancer 
related proteins, like BRCA1, or related drugs, like tamoxifen, were included in these 500 
pairs. All supporting evidence for each drug protein relations, a total of 5,225 PubMed 
abstracts, was manually curated to extract the relevant drug effect information. Out of 
those 500 pairs, 155 pairs contained information of how the drug affects the protein in the 
literature, totaling 19 drugs and 52 proteins. After performing manual curation, 79 drug 
protein pairs contained only up-regulation information, 57 only down-regulation 
information, 11 primarily up-regulation information, and 8 primarily down-regulation 
information. The distribution of directionality categories for breast cancer is shown in 
Figure 5-7a. A subnetwork based on the directionality information specific for Tamoxifen 
can be constructed from C
2
Maps directionality data (shown in Figure 5-7b). Another 
subnetwork based on the directionality information specific for Plicamycin is also shown 
in Figure 5-7e. 
iii. A case study on drug efficacy evaluation with C2Maps 
Drug efficacy can be measured by the ability of a drug to produce the desired phenotypic 
effect or molecular effect. To evaluate the drug efficacy in the molecular level based on 
our hypothesis illustrated in Figure 5-2, we need know how drugs can affect the 
expression of it interacting genes and how those genes expressed in disease conditions. 
We have got the former from the above case study of C
2
Maps. To get the latter, we did 
the differential analysis of a well-studied microarray dataset-GSE3191(116). This 
experiment contains breast cancer subtype luminal A, basal-like and also normal breast 
tissues. We obtained the differential genes for both breast cancer subtypes - luminal A 
and basal-like when compared to normal. We identified 579 differential genes between 
luminal A and normal, 773 differential genes between basal like and normal. We used 
these two sets for the following case study. 
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iv. Tamoxifen efficacy and toxicity assessment for the luminal A subtype 
Tamoxifen is a standard drug clinically used for breast cancer and has 15 interacting 
proteins with directionality annotations from C
2
Maps (shown in Table 5-5). We 
intersected differential genes from luminal A microarray experiment with Tamoxifen’s 
interacting partners from C
2
Maps. Four proteins out of 15 are differentially expressed 
between luminal A and normal, including ESR1. In Figure 5-7c, drugs are represented as 
hexagons and proteins as circles. The size of a protein node is proportional to the rp score, 
an indication of importance of this protein to breast cancer. Red nodes stand for over-
expressed proteins in breast cancer while green ones represent under-expressed proteins. 
For edges between drugs and proteins, red symbolizes that the drug activates the protein 
while green symbolizes inhibition. From the Figure, Tamoxifen has 3 therapeutic effects: 
it inhibits over-expressed ESR1, activates under-expressed JUN and activates MYC. 
Tamoxifen also has one toxic effect, activating over-expressed ERBB2, which might help 
explain certain side effects when using Tamoxifen. Considering that ESR1 is more 
significant for breast cancer compared with the other three proteins, overall, Tamoxifen 
has more of a therapeutic value in Luminal A patients by reversing the gene expression of 
important disease proteins in the network level (Figure 7c). 
Table 5-5.Tamoxifen relevant proteins and their directionality 
Drug Protein RpScore Association Direction 
Tamoxifen AKT1_HUMAN 82.99 1.77 1 
Tamoxifen BRCA2_HUMAN 21.14 3.29 1 
Tamoxifen CADH1_HUMAN 17.57 0.95 1 
Tamoxifen CDK2_HUMAN 2.94 2.12 1 
Tamoxifen E2F1_HUMAN 2.95 1.59 1 
Tamoxifen ERBB2_HUMAN 2.07 3.19 1 
Tamoxifen ESR1_HUMAN 72.39 5.11 -1 
Tamoxifen IRS1_HUMAN 2.51 1.29 -1 
Tamoxifen JUN_HUMAN 2.91 1.51 1 
Tamoxifen MYC_HUMAN 3.49 2.5 1 
Tamoxifen NCOA3_HUMAN 2.61 3.01 -1 
Tamoxifen NCOR1_HUMAN 2.81 4.05 1 
Tamoxifen P53_HUMAN 169.82 0.8 -1 
Tamoxifen P85A_HUMAN 2.92 1.57 1 
Tamoxifen PTEN_HUMAN 3.98 0.98 1 
Plicamycin MYC_HUMAN 3.49 4.16 -1 
Plicamycin SP1_HUMAN 3.32 6.24 -1 
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1 represents that the drug up regulates the protein while -1 represents down regulation. The 
association score was calculated based on the co-occurrence between the drug and protein. For 
details, please refer to (109). 
 
v. Tamoxifen efficacy and toxicity assessment for the basal-like subtype 
In Figure 5-7d, we portray the drug protein interaction for Tamoxifen in basal patients. 
Three proteins out of its 15 interacting proteins are differentially expressed between basal 
patients and normal. Tamoxifen has only 1 therapeutic effect by activating under-
expressed JUN, while 2 toxic effects by activating over-expressed E2F1 and inhibiting 
under-expressed IRS1. However, all these three proteins are relatively not important for 
breast cancer. This implies a neutral role overall when using Tamoxifen in basal patients 
since it is not able to reverse its interacting proteins in basal condition (Figure 5-7d). This 
agrees well with the clinical fact that basal or triple negative breast cancer patients fail to 
benefit from Tamoxifen treatment. 
vi. Plicamycinefficacy and toxicity assessment for the luminal A subtype  
Plicamycin was an approved antineoplastic antibiotic for a variety of advanced forms of 
cancer. It has been withdrawn from market in 2000. In Figure 5-7f, we showed the drug 
protein interaction for Plicamycin in Luminal A patients. It has 2 interacting proteins with 
directionality annotations (shown in Table 5-5) and both are not significant in breast 
cancer with a low rp score. Only 1 protein out of these 2 is differentially expressed 
between luminal A and normal. Plicamycin has a toxic effect overall by inhibiting under-
expressed MYC. This implied a neutral or toxic effect when using Plicamycin in Luminal 
A subtype breast cancer patients since it is not able to reverse its interacting proteins in 
the disease condition (Figure 5-7f). This may help explain why it was withdrawn in 2000. 
76 
 
 
 
Figure 5-7.Breast cancer case study for drug pharmacological effectevaluation 
with C2Maps.  
(a) Distribution of directionality categories for breast cancer; (b) A drug-target 
subnetwork with directionality information specific for Tamoxifen; (c) Drug effect 
evaluation for Tamoxifenon breast cancer subtype – luminal A; (d) Drug effect 
evaluation for Tamoxifenon breast cancer subtype – basal-like; (e) A drug-target 
subnetworkwith the directionality information specific for Plicamycin; (f) Drug effect 
evaluation for Plicamycinon breast cancer subtype – luminal A. 
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5.4 Conclusions 
In this study, we present an upgraded C
2
Maps platform to evaluate drug pharmacological 
effects based on the hypothesis that an ideal drug can reverse the gene expression level in 
a disease back to those in normal conditions. This online platform will enable users to 
query high-coverage protein-drug connectivity maps in real time. It enables users to 
research up-to-date knowledge of connectivity maps for a specific disease, explore 
therapeutic protein targets, design repurposed drug compounds, and assess toxicological 
impacts of drug compounds on disease-relevant genes/proteins. Three efficacy case 
studies prove the feasibility to apply the literature mined drug directionality data from 
C
2
Maps for drug efficacy study. It will be a major resource to biomedical researchers 
interested in developing disease-specific therapeutic and diagnostic applications based on 
progresses in network biology and network pharmacology. 
 
From the case study on breast cancer drug effect evaluation, we can see that there is still 
room for improvement, although the two breast cancer drugs get well-evaluated. The 
information for judging whether a drug have global therapeutic effects on other diseases 
is limited due to the manual curation procedure, while these information are very 
valuable for drug repurposing. In the current version of C
2
Maps, drug-protein pairs are 
mainly come from literature mining based on disease-gene searching and network mining, 
which can be supplemented by plenty of publicly-available drug target databases. One 
could continue to update C
2
Maps and improve its usability through achieving the 
following functionalities. 
1) One could increase the functionality of drug-orientated searching for relevant 
disease phenotypes and proteins in the C
2
Maps. It will allow users to input drug 
names, not just disease names. It should be able to retrieve all the disease names 
and genes/proteins related to this drug. This function will be very useful for drug 
repurposing. 
2) One could increase the functionality of disease-orientated browsing for relevant 
proteins and drugs in the C
2
Maps by using disease phenotype trees. It will allow 
users to browse the database by clicking the disease name. The current version 
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only supports the disease-specific searching function without any browsing 
function. 
3) One could also enhance the functionality of interactive directionality information 
annotation for drug-protein pairs in the C
2
Maps by using natural language 
processing (NLP) techniques. The literature curations for breast cancer, colorectal 
cancer and Alzheimer disease took three experts nearly one year’s effort to 
complete. While it ensure the data quality, it’s time consuming. With those golden 
standard dataset from curation, one could use NLP techniques to allow users to 
curate and annotate directionality information from PubMed abstracts more easily 
and semi-automatically. 
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Chapter 6. Drug Repositioning using Drug directionality Map (DMAP) 
 
This section is based on my work at (53). JYC guided the research team by providing 
ideas and feedback along the way, and revised the manuscript. HH constructed the 
DMAP, performed drug repositioning with K-S algorithms and drug similarity network 
approach, and wrote the manuscript.  
6.1 Introduction 
Repositioning of drugs (17, 22, 40) already approved for human use could alleviate the 
cost (41) associated with early stages and offer a shorter path for new approval(43). 
Current computational methods for drug repositioning include: (i) studying the structural 
similarity of each drug to their targets’ ligand set using chemoinformatic tools (45) or 
drug–drug and disease–disease similarity with machine learning methods(22), (ii) 
exploiting side-effect similarities (46), (iii) applying text-mining literature(23), or  (iv) 
matching drug and disease gene expression profiles (15, 17, 40, 47, 48).  Most of the 
approaches can only be applied to well characterized drugs whose targets or structures 
are known. Expression profile based approaches are, on the other hand, more general and 
do not require prior knowledge of the drugs.  
 
Although the Connectivity Map (CMAP) approaches are gaining popularity for 
expression profile based drug repositioning, the limitation of these approaches is due to 
the coverage of the dataset. Lamb et al.(15) developed a public available database called 
CMAP containing a collection of transcriptional expression data from cell lines treated 
with small molecules. Iorio et al.(40) proposed drug repositioning by constructing drug-
drug similarity networks from CMAP. Hu and Agarwal(47) and Sirota et al.(17) paired 
drugs and diseases whose gene expression patterns are negatively correlated. They further 
showed that the anti-correlation relationships between the drugs and diseases can suggest 
novel therapeutics for existing drugs. Despite of the success, the main limitation of 
studies based on CMAP (15) lie in the fact that it is simply impossible to screen all the 
drugs in the database due to experimental cost.  
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Critical to the success of the expression profile based drug repositioning is the resource 
for how drug affects the disease proteins. In this work we developed a computational 
Drug directionality Map (DMAP) database which contains ranked drugs’ effects (i.e. 
activation or inhibition) on their interacting proteins (Figure 6-1). The database offers a 
better coverage consisting of directed drug-protein relationships for 328,676 drugs. To 
check its quality for drug repositioning, we applied the following two representative 
CMAP based drug-repositioning methods in literatures: (i) we calculated pairwise drug 
similarity (40) based on the DMAP for drug repositioning, (ii) we implemented the 
Kolmogorov–Smirnov algorithms (15, 17) based on the dataset from DMAP. We not 
only successfully recalled known drugs for breast cancer, colorectal cancer, lung cancer, 
diabetes, etc. but we were also able to propose novel indications for drugs in 
NCATS(117).  
 
Figure 6-1. Computational framework.  
 
6.2 Methods 
i. Construct the DMAP data set   
DMAP contains drug protein/gene directionality information in a compatible format with 
CMAP. The main data sources for DMAP are STITCH(32) and HAPPI (80). STITCH is 
an aggregated Cheminformatics database of interactions connecting over 300,000 
chemicals and 2.6 million proteins. We first parsed out chemical protein interactions for 
Homo sapiens with those edge actions being activation or inhibition. Next we did a 
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probabilistic weighted average summary of all the evidence to come up with the overall 
action for each specific chemical-protein relationship.  
 
To rank each relationship, we used HAPPI (80), an integrated protein interaction database 
including HPRD, BIND, MINT, STRING, and OPHID to assign a weight for each drug’s 
interacting proteins (60). Finally, we developed an intuitive pharmacology score, or P-
Score, to combine the probability for each interaction and the weight of the interacting 
protein: 
P-Score(d,p)=conf(d,p)×weight(p)                                                                                   (1)    
Here, d and p are specific drugs and proteins, respectively. conf(d,p) measures probability 
of each drug-protein relationship with a positive sign to indicate activation and a negative 
sign to indicate inhibition. It is thus within a range of [-1,1]. weight(p) is the 
measurement of the importance of the protein in the pathway as shown in the function (2)                                                                                              
                                                                 (2)  
Here, p and q are proteins on the pathway, k is an empirical constant (k=2 in this study), 
conf(p, q) is the confidence score assigned by HAPPI to each interaction between protein 
p and q, and N(p, q) holds the value of 1 if the protein p interacts with q. 
 
P-Score contains both the information of each drug’s action on their interacting proteins 
and the importance of their proteins in the biological network. This is different than the 
expression level based ranking in CMAP, which may be more suitable for biomarker 
discovery instead of drug discovery. With P-Score for each drug-protein relationship, 
DMAP is thus in a compatible format with CMAP (15). 
 
Compared to STITCH alone, DMAP differed in that i) it left out ‘spurious’ drug protein 
relationships by requiring the interacting protein to have biological significance as 
measured by the protein interactions in HAPPI; ii) it assigned P-Score to the drug protein 
relationship with Equation (1), different from the pure probabilistic score in STITCH 
database.  
)),(ln()),(ln()(    qpNgpconfkpWeight NETqNETq
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ii. Integrate drug therapeutic indication data 
For repositioning existing drugs for other uses, we need have the approved indications for 
each drug. Thus we integrated the Therapeutic Target Database (TTD) (118) and the 
dataset from the PREDICT (22) paper to come up with a list of known drug indications. 
TTD is a database that provides information about drugs’ known therapeutic protein 
targets and their targeted diseases. The PREDICT (22) paper provides a compiled list of 
drug indications. We integrated these two sources to get 2,912 drug indication 
associations corresponding to 1,180 drugs and 726 indications. 
iii. Prepare disease expression signatures and drug expression signatures   
The expression based drug repositioning need the disease gene expression as inputs. We 
retrieved the disease gene expression profiles from Pacini C et al. (119)’s paper. In total, 
87 disease associated microarray experiments were compiled to represent 45 distinct 
diseases. According to Pacini C’s paper, these datasets were obtained from the GEO 
microarray repository (120). The raw CEL files were normalized with RMA(121). For 
those gene expression profiles representing the same disease, they were combined with 
the median rank normalization by Warnat et al.(122). 
 
The drug gene expression datasets were obtained from Iorio et al.(40)’s paper instead of 
directly from CMAP (15) to reduce the batch effect. Iorio et al.(40) computed a single 
synthetic ranked list of genes, called Prototype Ranked List (PRL), by merging all the 
ranked list of the same compound in CMAP. Only consistently 
overexpressed/underexpressed genes are placed at the top/bottom of the RPL. This helped 
capture a consensus transcriptional response for each drug. We thus chose to use the PRL 
to represent the drug signatures from CMAP in this study. 
iv. Design drug similarity measurement  
To measure the similarity among each drug pair, we computed SIM(dx,dy) based on the 
Tanimoto Coefficient between their interacting proteins (3) 
SIM(dx,dy)=
                   
   ∪   
                                                                                        (3)  
Here, dx  and dy  represent the two specific drugs.     represents the set of interacting 
proteins for dx.    represents the set of interacting proteins for dy.    ∪     is the number 
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of total distinct proteins in   and   .           is the number of overlapped proteins 
on which both drugs have consistent effects (i.e. both activate or inhibit the shared 
proteins).           is the number of overlapped proteins on which the drug pair have 
in-consistent effects (i.e. one activates while the other inhibits the shared proteins). 
SIM(dx,dy) lies in the range of [-1,1] with 1 representing that the two drugs share the same 
interacting proteins and drugs’ action on each protein is the same while -1 representing 
that the two drugs share the same proteins but drugs’ action on each protein is opposite.  
v. Implement Kolmogorov–Smirnov strategy  
We implemented the nonparametric, rank-based strategy based on the algorithm 
originally introduced by Lamb et al.(15) to generate a ranked list of candidate drugs for 
each disease. For each disease signature, we computed an enrichment score separately for 
the up- or down- regulated genes: esup and esdown. In specific, we constructed a vector V 
of the position of each of the up- or down- regulated genes on the basis of the values from 
the reference drug dataset. The vector was then sorted in ascending order such that V(j) is 
the position of disease gene j. The computation of the enrichment score is based on 
Kolmogorov–Smirnov statistic and the details can be referred to in the supplementary 
material in Lamb et al. (15). The drug score is set to zero, where esup and esdown have the 
same algebraic sign. Otherwise, we set the drug score to esup-esdown. We hypothesized 
that those drugs with a statistically significant negative score might be a possible 
treatment for the disease of interest. 
vi. Perform literature validation  
To check whether the predicted drug-disease pairs have clinical literature evidence, we 
used the esearch API provided by NCBI. The query term we used is ‘drug name AND 
disease name AND (Clinical Trial[ptyp] OR Clinical Trial, Phase I[ptyp] OR Clinical 
Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial, Phase 
IV[ptyp])’. The total number of clinical type PubMed articles for each association was 
recorded. 
6.3 Results 
i. Drug directionality Map (DMAP) Construction 
We constructed a probabilistic-based Drug directionality Map (DMAP). It records the 
directionality (i.e. activation/inhibition) between chemicals and their interacting proteins 
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and the strength of such directed relationships. To generate a ranking for each 
relationship, we developed an intuitive pharmacology score by combining the probability 
of a drug’s action (i.e. activation/inhibition) and the significance of each interacting 
protein. This ranking system renders DMAP in a format essentially compatible with gene 
expression profiles in CMAP. Therefore, DMAP serves as a valuable alternative for 
researchers interested in CMAP based studies. 
 
DMAP contains 9,486,081 ranked chemical protein interactions for 328,676 chemicals. It 
significantly increases the chemical coverage by over 200-fold (Table 6-1) compared to 
the 1,309 chemicals covered in the second release of CMAP (15). A Venn diagram shows 
the number of shared chemicals between DMAP, CMAP and drugs with known 
indications which we compiled from the TTD database(118) and literature (22) (Figure 6-
2). CMAP contains 394 drugs with known indications. Among these, 380 drugs can also 
be captured by DMAP and thus only 14 drugs are uniquely covered by CMAP. On the 
other hand, 982 drugs in DMAP have known indications. Among these, 602 drugs are 
uniquely covered by DMAP. Thus, we argue that DMAP provides a valuable resource for 
repositioning existing drug for new uses. To demonstrate this, in the following section we 
applied two representative drug-repositioning methods with DMAP dataset and proved its 
utility for computational drug repositioning.    
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Table 6-1.Statistics summary of DMAP 
Performance indicator CMAP (build 02) DMAP Version 1.0 (Oct 
2013) 
Count of drugs  1,309 328,676 
Count of drugs with known 
indications 
394 982 
Count of drug protein 
relationship 
15,472,380 9,486,081 
Count of up regulations 7,710,741 4,458,335 
Count of down regulations 7,763,186 5,027,746 
 
ii. DMAP’s utility for drug repositioning  
To check DMAP’s utility for drug repositioning, we applied the following two known 
drug-repositioning methods in literatures: (i) drug similarity approach, (ii) Kolmogorov–
Smirnov algorithms. The former approach was nearest neighbor based approach: if two 
drugs were similar, the disease indication for one drug could be potentially assigned to 
the other drug. The latter approach was a hypothesis driven approach. It assumed that the 
ideal drug could reverse the gene expression in the disease condition back to that in the 
healthy condition. This approach had more structural assumption imbedded and thus was 
 
 
Figure 6-2.The Venn diagram of drugs from DMAP drug signatures, CMAP 
drug signatures and drugs with Indication 
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different from the similarity based approach. These two approaches were the two 
mainstream drug repositioning approaches. 
a) Drug similarity network approach based on DMAP  
 
We first checked the quality of DMAP by applying them for drug repositioning with the 
drug similarity network approaches developed by Iorio et al.(40). We computed 481,671 
pairwise drug similarities for the 982 drugs with known indications by calculating the 
Tanimoto Coefficient between their interacting proteins profiles. 
 
 
 
Figure 6-3. A schematic representation of the GBA method.  
Given two drugs x and y and their corresponding indication profiles Ix and Iy, 
respectively, the potential novel uses for drug x is Iy,x. Similarly, potential novel 
drug uses for drug y is Ix,y. 
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To assess the prediction performance, we implemented the ‘Guilt by Association’ (GBA) 
concepts (Figure 6-3.) presented by Chiang et al.(126) and conducted “Leave-One-Out” 
cross-validation. For each drug, we removed its known indications and attempted to 
recover them by considering the indications for its top N similar drugs found. We 
calculated overall sensitivity and specificity by varying N—the number of similar 
drugs—from 1 to 981. The area under the ROC curve (AUC) score was used to measure 
the performance. 
The Overall AUC for the prediction based on DMAP achieved 0.82. Most importantly, 
early retrieval performed well, with a partial AUC of 0.72 for specificity of 90% or 
above(127). Since one could only test the limited number of drugs in experimental setting, 
the good performace in high specificity region, approximately corresdponing to the top 
 
Figure 6-4. ROC curves for the prediction performance based on DMAP (blue 
line), STITCH (yellow line) and CMAP (red line).  
Blue shade area provides a partial ROC area corresponding to specificity 90% above.  
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ten candidates of all the predictions, would make the proposed drug repositioning more 
mearningful in practice. 
 
In comparison, 1) we performed similar analysis based on CMAP transcriptome data and 
the overall AUC was 0.64. The early retrival performance was only 0.55; 2) we 
performed the analysis directly using the STITCH data and we got an overall AUC of 
0.70. The early retrival performance was only 0.65. Figure 6-4 showed that the ROC 
curve based on DMAP was above the curve from STITCH which was in turn above the 
curve of CMAP.  
 
To rule out the possibility that the performance difference was purely due to the drug 
coverage difference between DMAP and CMAP, we conducted the ROC analysis with 
only the shared drugs  between DMAP and CMAP. The DMAP achieved an AUC of 0.81 
while CMAP only achieved an AUC of 0.64 (Figure 6-5). 
 
Out of all the possible drug pairs, we identified 3,014 significant pairs by requiring the 
number of overlapped proteins no less than two and the drug similarity score at the top 
5% of the distribution. The resulting drug network (Figure 6-6A) showed a scale free 
property (Figure 6-6B), commonly observed in a biological network. Most of the drugs 
are well connected and formed communities. In fact, 451 drug pairs out of these 3,014 
significant pairs have shared at least one known disease indication. For the remaining 
2,563 pairs without overlapping indications, the novel drug disease associations from 
1,206 drug pairs were supported by at least one clinical type PubMed article. Table 6-2 
list the top 20 drug-disease pairs and could be a good starting point for further 
experimental validations.  
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Figure 6-5. The ROC curves for DMAP and CMAP using the overlapped drugs.  
 
Table 6-2.Top 20 novel drug repositionings and the number of clinical type 
publication support 
Drug Disease PubMed(Clinical) 
Rocuronium Pain 126 
Clemastine Allergies 80 
Mometasone Asthma 78 
Nicotinamide Alzheimer Disease 45 
Sotalol Hypertension 42 
Sertraline Alzheimer Disease 40 
Ifosfamide Leukemia, Acute Myeloid 40 
Gabapentin Anxiety disorder 33 
Vinorelbine Prostate Cancer 32 
Lumiracoxib Pain 28 
Hydrocodone Anesthetic 25 
Zileuton Inflammatory diseases 20 
Irbesartan Cardiovascular disease 17 
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Moclobemide Parkinson Disease 13 
Fluvoxamine Alzheimer Disease 10 
Ranolazine Dysrhythmias 6 
Trihexyphenidyl Depression 5 
Nicotinamide Breast Cancer 5 
Methylphenidate Obesity 5 
Pemetrexed Colon cancers 1 
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Figure 6-6. (A) Drug similarity network based on DMAP. (B) Power-law degree 
distribution of the network.  
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b) Kolmogorov–Smirnov approach based on DMAP 
We next applied DMAP with the nonparametric Kolmogorov–Smirnov strategy based on 
the methodology originally developed by Lamb et al.(15).  We followed (15) and (17) to  
use the recall of known drug indication relationship as the performance measurement for 
better benchmarking with previous works. We compiled the gene expression profiles for 
45 distinct diseases and then queried them against DMAP and CMAP, respectively, to 
generate a ranked list of potential treatments for each of the diseases of interest. We 
calculated a similarity score for every drug-disease pair. If the similarity score is negative, 
the drug overall causes a reverse set of changes in the gene expression compared to that 
in disease condition. We hypothesized that this drug could potentially have therapeutic 
effects for that particular disease. To evaluate the statistical significance of the similarity 
score, we applied a permutation approach by randomly selecting any drug signatures and 
re-calculated the similarity score accordingly. We did the permutation 200 times for each 
drug-disease pair and computed the p-value by checking the actual similarity score with 
the score distribution after randomization. 
 
We examined results for diseases that are the leading causes of death in the US (128). For 
breast cancer, we successfully retrieved Anastrozole, Capecitabine, Doxorubicin, 
Estradiol, Megestrol, Paclitaxel, Testosterone and Testolactone as possible therapeutic 
drugs for breast cancer. When the CMAP dataset was utilized, only Paclitaxel was 
retrieved as a potential therapeutic drug. For lung cancer, we retrieved Cisplatin and 
Etoposide by using the DMAP. However, when CMAP was used, we were not able to 
retrieve any drugs for lung cancer. Table 6-3 also contains the results for other diseases. 
To have statistical significance, we required the p-value less than 0.05 in Table 6-4. 
CMAP did relatively better in the case for Alzheimer's disease and Leukemia. For these 
known relationships covered in CMAP but not DMAP, or vice-versa, some were due to 
having borderline p-value while others were due to violating our hypothesis of negative 
correlation. Overall, DMAP and CMAP database were complimentary to each other. 
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Table 6-3.Retrieval of known disease drug relationships from DMAP and CMAP, 
respectively 
The star rating is labeled according to the following criteria: 
K-S Score<-0.3:                            
-0.3 K-S Score<-0.2:                 
-0.2 K-S Score<-0.1:                 
-0.1 K-S Score<0:                      
K-S Score 0 or p-value 0.05: 
 
Disease Drug DMAP CMAP 
Breast Cancer Anastrozole   
Breast Cancer Capecitabine   
Breast Cancer Doxorubicin   
Breast Cancer Estradiol   
Breast Cancer Megestrol   
Breast Cancer Paclitaxel   
Breast Cancer Testolactone   
Breast Cancer Testosterone   
Colorectal Cancer Capecitabine   
Colorectal Cancer Leucovorin   
Colorectal Cancer Raltitrexed   
Lung Cancer Cisplatin   
Lung Cancer Etoposide   
Prostate Cancer Docetaxel   
Prostate Cancer Leuprorelin acetate   
Parkinson's disease Galantamine   
Parkinson's disease Trihexyphenidyl   
Alzheimer's disease Galantamine   
Alzheimer's disease Memantine   
Alzheimer's disease Tacrine   
Diabetes Liraglutide   
Diabetes Vildagliptin   
Leukemia Carmustine   
Leukemia Celecoxib   
Leukemia Idarubicin   
Leukemia Irinotecan   
Leukemia Isotretinoin   
Leukemia Methotrexate   
Leukemia Pentostatin   
Asthma Bambuterol   
Asthma Dexamethasone   
Asthma Methylprednisolone   
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Asthma Orciprenaline   
Asthma Prednisone   
Asthma Salbutamol   
Asthma Salbutamol sulphate   
Asthma Theophylline   
 
Besides recalling the known drug-disease relationships, this method could also propose 
novel drug-disease associations. National Center for Advancing Translational Sciences 
(NCATS) (117) provides a list of drugs for translational medicine researches. We cross 
checked the novel predictions with their drug list. Here, we highlight a few drug-disease 
relations.  
 
A novel relation that DMAP results suggest is between Vincristine, a drug typically used 
for Leukemia, and Wilm’s tumor. A recent study performed by Indolfi et al.(129) 
revealed that there is a potentially higher rate of survival in patients with bilateral Wilm’s 
tumor when patients are given a dosage of vincristine/actinomycin D.   
 
Nifedipine is usually used to treat high blood pressure and angina. The DMAP results 
suggest that Nifedipine can also be used to treat asthma. Since Nifidipine is a PKC 
inhibitor and PKC is a potential therapeutic target for asthma (130), it is a potential 
treatment for asthma. Cheng et al.(131) demonstrated in their study that Nifedipine can 
help control the constriction involved in sensitized tissue in asthma.  Furthermore, 
another study by Barnes et al.(132) suggested that Nifidipine modifies exercise-induced 
asthma. 
 
Progesterone is a prescription drug used for women taking estrogens after menopause and 
is also used for treating amenorrhea. The DMAP results suggest that progesterone can be 
used to treat breast cancer. In the study by Groshong et al. (133), it was determined that 
treatment with Progesterone can be used to regulate Breast Cancer cell growth.  
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Table 6-4 summarized the all the novel drug repositioning predicted by both similarity 
approach and KS algorithms, which could be starting point for further experimental 
validation. 
 
Table 6-4. Drug repositioning predicted by both similarity approach and KS 
algorithms 
Drug Disease Indication 
Mebendazole Alzheimer's disease 
Amiodarone Asthma 
Anastrozole Asthma 
Anastrozole Asthma 
Anastrozole Asthma 
Benztropine Asthma 
Chlorzoxazone Asthma 
Drospirenone Asthma 
Econazole Asthma 
Fluvoxamine Asthma 
Itraconazole Asthma 
Methylergonovine Asthma 
Methylergonovine Asthma 
Methylergonovine Asthma 
Oxybutynin Asthma 
Oxybutynin Asthma 
Rivastigmine Asthma 
Sertraline Asthma 
Sitaxsentan Asthma 
Tioconazole Asthma 
Tioconazole Asthma 
Vinorelbine Asthma 
Amodiaquine Breast Cancer 
Atovaquone Breast Cancer 
Flucytosine Breast Cancer 
Fluticasone Propionate Breast Cancer 
Fluvoxamine Breast Cancer 
Methylergonovine Breast Cancer 
Raltitrexed Breast Cancer 
Repaglinide Breast Cancer 
Rivastigmine Breast Cancer 
Spirapril Breast Cancer 
Tioconazole Breast Cancer 
Trifluridine Breast Cancer 
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Trimethoprim Breast Cancer 
Voriconazole Breast Cancer 
Zafirlukast Breast Cancer 
Atovaquone Colorectal Cancer 
Cyclizine Colorectal Cancer 
Flucytosine Colorectal Cancer 
Suprofen Colorectal Cancer 
Tolcapone Colorectal Cancer 
Trifluridine Colorectal Cancer 
Valdecoxib Colorectal Cancer 
Acenocoumarol Parkinson's disease 
Anastrozole Parkinson's disease 
Bivalirudin Parkinson's disease 
Capecitabine Parkinson's disease 
Cyclizine Parkinson's disease 
Pyrimethamine Parkinson's disease 
Suprofen Parkinson's disease 
Valdecoxib Parkinson's disease 
Flucytosine Prostate Cancer 
Rivastigmine Prostate Cancer 
Trimethoprim Prostate Cancer 
Trimethoprim Prostate Cancer 
Voriconazole Prostate Cancer 
 
6.4 Conclusions 
Critical to drug repositioning involves the reliable measurements of how drug affect 
disease proteins. In this work we presented a computational drug directionality resource 
called DMAP to address the challenges. We demonstrated that the resource can greatly 
facilitate the drug discovery process for the following reasons: access to disease gene 
drug relationship data with high coverage and quality; incorporating prior knowledge 
about biological significance with protein interaction network.  
 
This study differs from previous research in that it provides a comprehensive database of 
computationally derived drug-protein relationships. Previous efforts (17, 40, 47, 48) on 
paring the expression of drugs and diseases mainly rely on experimental connectivity 
map. For example, Sirota et al.(17) performed a large-scale integration of expression 
signatures of human diseases from the public data with CMAP drug signatures. This 
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work provides another alternative resource of directed drug-protein relationships. The 
drug similarity study proves the validity of the probabilistic based directionality for each 
drug-protein relationship. The implementation of K-S algorithm proves the compatibility 
of the pharmacology score based ranking with the expression based ranking in CMAP for 
the drug repositioning research. With these two major drug repositioning approaches, the 
knowledge base from DMAP performed better than directly using the microarray data 
from CMAP. It can thus serve as a valuable resource for drug repositioning studies. 
 
One limitation of DMAP lies in that the number of interacting proteins for each drug is 
not a constant number. For the gene expression based profiles in the CMAP database, 
each drug was measured against the same number of proteins in experiments while in 
DMAP the number of interacting proteins varies from drug to drug In DMAP, 64,034 
drugs have at least 10 activated and inhibited proteins. 13,098 drugs have at least 50 
activated and inhibited proteins and 3,515 drugs have at least 100 activated and inhibited 
proteins. Despite of this limitation, the database served its purpose for systematic drug 
repositioning as demonstrated in this work. 
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Chapter 7. Drug Repositioning using Side Effect Features: from 1D to 2D 
This section is based on my work at (54). HH and LY conceived the idea. HH constructed 
the drug combination database, built the decision tree model, evaluated the prediction 
performance, validated the out of sample predictions and wrote the manuscript. XAQ 
helped analyze the case studies.   
7.1 Introduction 
The use of multiple drugs with different mechanisms or modes of action may treat the 
disease more effectively (142-144). The traditional “one drug – one target – one disease” 
approach has been used to develop successful drugs. However such "magic bullet" 
sometimes shows limited efficacy, especially for complex diseases (145). It is often due 
to factors such as network robustness (146), redundancy (147), compensatory and 
neutralizing actions (148).  Polypharmacology, which focuses on multi-target drugs, has 
the potential (11) to address those limitations. High-throughput screening was used to 
identify possible drug combinations (149); however, it is impractical to screen all 
possible drug combinations for every indication. Therefore, computational methods (150-
153) have been developed to predict new drug combinations. For example, network 
biology was introduced to investigate drug combinations by studying the molecular 
networks or pathways affected by the drugs (154)  yet the incompleteness of molecular 
networks limits the practical use of such approaches for prediction of novel drug 
combinations. 
 
Besides the molecular information-based approaches, clinical phenotypic information has 
not been adequately investigated for its power in predicting drug combinations. The 
advantages of leveraging on clinical phenotypic information include better translational 
power when comparing with animal models (155) since it mimics a phenotypic screening 
of the drug effects, both therapeutic effect (46, 156) and toxic effect (157, 158), on 
human. In this work we propose an innovative approach by using observed side effects 
reported in clinical findings to identify novel safe and efficacious drug co-prescriptions or 
fix-dose combinations.  
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In this study, we summarized the prediction of novel drug combination as a two-step 
effort: 1) to minimize the potential side effect of the new combination; 2) to avoid 
reduction of the efficacy via pairing the indication for each drug in the new combination. 
We hypothesized that drugs that can be put together usually do not have serious adverse 
drug reactions (ADRs) in common. We tested this hypothesis by identifying a set of three 
FDA blacklisted side effects from marketed drug combinations and evaluated its 
prediction performance in both the training and the validation set. Our results support that 
using these features, clinicians could rule out unsafe drug pairs with high confidence. We 
further demonstrated such classification power is not due to the synthetic confounding 
factors such as biased disease indications or drug targets. We further proposed both 
components in the pair to treat the same disease so that therapeutic effects from each 
component could be added in the combination. This two-step rule provides a novel 
approach to identify novel drug co-prescriptions or combination from using of clinical 
side effects, which should be less of a translational issue compared to animal model. We 
applied this approach to identify 977 candidate drug combinations. 144 pairs (15%) are 
supported by clinical trials from clinicaltrial.gov for the same indication, leaving 85% 
potential novel combinations to be evaluated in future clinical studies. 
7.2 Methods 
i. Preparation of datasets 
Side effect datasets. SIDER is a side effect database containing information on marketed 
medicines and their recorded adverse drug reactions. The information is extracted from 
public documents and package inserts (159). In this study, we downloaded the entire 
database from http://sideeffects.embl.de/. Besides relying on drug label as sources for 
drug side effects, we also checked FAERS, a database that contains information on 
adverse event submitted to FDA and is designed to support the FDA's post-marketing 
safety surveillance program for drug and therapeutic biologic products. OFFSIDES is 
such a side effect database by mining FAERS system while controlling those 
confounding factors such as concomitant medications, patient demographics, and patient 
medical histories and so on. OFFSIDES contains 1332 drugs and 10097 side effects. 438 
drugs and 2322 side effects are shared between SIDER and OFFSIDE. In the final 
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integrated side effect database, drugs are represented with STITCH ID while side effects 
represented with MedDRA terms so that they could be integrated across databases. 
 
The TWOSIDES database identifies 59,220 pairs of drugs with 1,301 adverse events by 
carefully matching groups of patients in the post-marketing surveillance system FAERS. 
It provides a reliable and comprehensive database of side effects for drug pairs.  It is thus 
used to identify the features enriched in approved DDCs compared to random drug pairs. 
In contrast, when doing the DDC prediction, we only used the side effect for single drugs 
from drug label and OFFSIDES since it is logical to only have single drugs’ side effect 
data before such pair has come into being.  
 
Drug combination datasets. The Drug Combination Database (DCDB) is a database 
collecting and organizing known examples of drug combinations. The current version 
contains 145 drug combinations. Peer Bork’s paper also lists 178 drug combinations, 
mainly collected from FDA orange book. We also curate 236 FDA approved or registered 
drugs from literature. After mapping them to STITCH ID, we get a comprehensive list of 
349 drug combinations.  
 
Drug target and ATC code. DrugBank (http://www.drugbank.ca) is a unique 
bioinformatics and cheminformatics resource that combines detailed drug data with 
comprehensive drug target information. Current version contains 6711 drugs and 4081 
targets. We downloaded the full database in xml format and parsed out the drug target 
pairs and drug ATC pairs.  
ii. Analysis methods 
Two Step Rule for making safe drug combination or co-prescriptions. First step is to 
make sure what drugs can be safely put together. We hypothesize that the drugs that can 
be put together usually do not have overlap in some serious adverse drug reactions 
(ADR), but might share some side effects that contribute to the therapeutic effect (46, 
156). Here we came up with a practical black list consisting of three side effects for 
clinicians to decide the safe drug pairs with high accuracy; at the second step, we 
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required that those safe pairs should further have the same disease indications to achieve 
the similar efficacy (Figure 7-1). 
Feature selections For each side effect, we built a two by two table and performed a 
Fisher's exact test to determine whether that side effect is differentially shown up 
between positive DDCs and negative DDCs. Then we used p-value less than 0.05 as the 
threshold to pick the significant features. When we developed the black list consisting of 
three side effects, we first used information gain as the statistical significance 
measurement to identify the top ten features. To get the biological significance, we then 
chose three out of the top ten according to the origin of their organs/human systems. 
 
Machine learning models we used decision tree as main machine learning models, J48 
decision tree algorithms in WEKA(160). We also tested the performance with Naïve 
Bayes, Logistic regression and random forest. All of them gave even better AUC and 
accuracy than decision tree.  Since we are more interested to develop a simple rule to be 
 
 
 
Figure 7-1. Illustration of the Two-Step Rule to predict the drug combinations. 
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easily applied in clinical than achieving a better AUC, we presented the results based on 
decision trees model in this work. 
 
PubMed and Clinical Trial Validation To validate whether the predicted drug pairs 
have clinical literature supports, we used the esearch API provided by NCBI to count the 
co-occurrence of the drug components for each proposed DDCs. The query term we used 
are ‘drug name1 AND drug name2 AND (Clinical Trial[ptyp] OR Clinical Trial, Phase 
I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical 
Trial, Phase IV[ptyp])’. We also checked clinicaltrial.gov to see whether predicted drug 
pairs are co-mentioned in the same registered clinical trials.  
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7.3 Results  
i. Construction of the data set  
We constructed a comprehensive drug combination database (Figure 7-2A) which 
contains 349 approved pair-wise drug-drug co-prescriptions/combinations (DDC) from 
three different sources: drug combination database DCDB (161), a recent drug 
combination paper (153) and manual  literature curation of the FDA approved or 
registered DDCs. To resolve different naming issues in different data sources, DDCs 
were represented by their two components whose names were mapped to STITCH ID 
(32) for comparison. (Venn diagram comparison of these three sources was shown in 
Figure 7-3) 
 
To annotate drugs with their side effect features, we extracted side effect information 
from drug labels using SIDER (159) and OFFSIDES (157) (Figure 7-2B) . SIDER 
 
Figure 7-2. Workflow of applying logistic regression and decision tree models to 
measure the DDC prediction performance with side effects as features 
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derives side effects from drug labels and OFFSIDES mines side effects from post-
marketing surveillance system FAERS (i.e. FDA Adverse Event Reporting System). Of 
the 349 approved DDCs, 239 DDCs can be annotated with side effects for both 
components, which correspond to 245 individual drugs and 7,888 side effects. As a 
comparison, previous work (153) used 181 pair-wise DDCs, out of which only 75 
contains both side effects and indication annotation due to the limited data sources for 
DDCs, side effects and indications. Therefore the coverage of this database is much more 
comprehensive. 
 
  
 
Figure 7-3. The Venn diagram of drug combinations, where the numbers 
indicate how many drug combinations can be covered by each data source 
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We also constructed a negative training set consisting of unsafe drug pairs for training the 
DDC prediction model. We defined the unsafe co-prescriptions as those causing 
unexpected side effects as tracked in TWOSIDES (157), a database of reported side 
effects only caused by the combination of marketed drugs rather than by any single drugs 
from FAERS. For those 245 drugs in the positive set, we generated all the possible pairs 
of combinations while excluding those 239 positive DDCs. Then the left drug pairs were 
overlapped with those drug pairs in TWOSIDES.  A resultant set of 2291 unsafe drug 
pairs (8% of all the possible drug combinations for the 245 drugs) were identified and 
used as the negative training set for training the DDC prediction model.  
 
 
Figure 7-4. Evaluation of logistic regression and decision tree models based on 
the full dataset (i.e., 239 marketed DDCs and 2291 unsafe drug pairs).  
(A) ROC curve. (B) Precision-Recall curve. 
 
106 
 
ii. Evaluation of the power of predicting DDCs based on the side effects features 
We used 239 marketed DDCs as positive set along with 2291 unsafe drug pairs as 
negative set. Each side effect of a drug is called a feature and a drug pair can be 
represented as a vector of side effect features with value of 0, 1 and 2 depending whether 
zero, one or both drugs have such side effect. We applied logistic regression model with 
10-fold cross validation to evaluate the performance. We measured the model 
performance with both AUC (area under the ROC curve) and AUPRC (area under the 
precision-recall curve). We repeated the cross-validation experiment 100 times with 
random seeds, and computed the mean and the standard deviation of AUC and AUPRC 
over the 100 repetitions. In the experiment, logistic regression model achieved an AUC 
of 0.92±0.01 and AUPRC of 0.86±0.01 (Figure 7-4). The overall AUC is 0.94 and the 
early retrieval performs as well with a corrected pAUC of 0.92, which enables us to keep 
false positives low (162) while sacrificing some true positives.  
 
To explore how unbalanced positive set and negative set affects AUC, we randomly 
sampled from the negative set 100 times. Each time we made the negative set with the 
same number of drug pairs with positive set. The average AUC was 0.95 (Figure 7-5) 
with standard deviation of 0.02. 
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Figure 7-5. Evaluation of logistic regression based on 239 marketed DDCs with 
balanced positive set and negative set.  
 
To exclude the fact that the good AUC score is just due to homologous relationships 
between structurally similar drugs, we mimicked the method in Gottlieb’s work (163) by 
removing the drug pairs with Tanimoto similarity coefficient larger than 0.50. We re-run 
the logistic regression 10-fold cross-validation experiment 100 times and still achieved 
AUC of 0.92±0.01 and AUPRC of 0.86±0.01,which is the same with previous results to 
two decimal places. 
 
Since the datasets are made of drug pairs, it is possible that some drugs occur in both the 
training set and testing set although no drug pairs are shared between these two sets. To 
further characterize the predictive model, hold-drug-out validation had been used to 
evaluate the performance of the method. The original 2530 drug pairs are made of 245 
distinct drugs. From the 245 drugs, we randomly chose 60 drugs as testing drugs (i.e., 
about 25%) and 185 drugs as training drugs (i.e., about 75%). We held out all drugs pairs 
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involved with the testing drugs, rather than holding out drug pairs directly. From the 2530 
drug pairs, we selected the pairs only involving with training drugs as training data. Then 
we constructed predictive models with the training data. From the 2530 drug pairs, we 
selected the pairs only involving with testing drugs as validation data for testing the 
models. Again, we repeated the hold-drug-out validation experiment 100 times with 
randomly partitions, and computed the mean and the standard deviation of AUC and 
AUPRC over the 100 repetitions. In the experiment, logistic regression model achieved 
an AUC of 0.87±0.03 and AUPRC of 0.76±0.07. The additional results show that the 
predictive model performed still well even in the situation where none of the pair 
members in the test set are within the training set.  
 
The results of logistic regression showed the strong performance of the DDCs prediction 
with side effect features. Next we focused on how to develop a simple rule for the 
 
Figure 7-6. The outline of this study 
 (A) build logistic regression models to measure the DDC prediction performance with 
side effects as features; (B) build rule based model that can be easily applied in 
clinical settings 
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clinicians or the drug developers to use in their daily work in making co-prescriptions or 
fix-dose drug combination (Figure 7-6). A different model, decision tree model (164), 
was thus tested. The model showed an AUROC of 0.83±0.01 and AUPRC of 0.71±0.01, 
not as good as the performance in the logistic regression model. However considering 
that decision tree model is easier for interpretations in practice and such a white-box 
model is much more accessible to clinicians, we used the decision tree model for the 
further analysis. 
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For the prediction test set, we used all the possible pair-wise drug combinations of 245 
marketed DDCs, excluding both positive and negative set. In total 27,360 drug pairs were 
used as prediction test set. With the trained decision tree model, we made the prediction 
on the testing set and only pairs with predicted probability above 0.99 and co-occurred in 
at least 10 publications of clinical trial publications in PubMed were considered as 
candidate DDCs. As a result, 1508 drug pairs were identified and they formed a well-
connected network (Figure 7-7A) and the degree distribution is approximately a Power-
law Distribution (Figure 7-7B). This well-connected network indicates that those drugs in 
 
Figure 7-7. Drug combination networks. 
(A) A network view of the 1508 drug pairs with prediction probability above 0.99 and 
support from at least 10 clinical type publications.(B) Degree distribution of the 
network. (C) The sub-network cluster. (D) A network view of the 11 drug pairs with 
prediction probability less than 0.01 and support from at least 10 clinical type 
publications. The edge width is proportional to number of clinical literature supports. 
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the network are inherently promiscuous to each other and would have a higher potential 
to be combined with their close neighbors we further identified a condensed sub-network, 
highly interconnected regions in the network (Figure 7-7C) with Cytoscape (86) plugin 
MCODE (165). The connections between the hub drugs include some known drug 
combinations like hydrocortisone and dexamethasone (immunosuppressants) (166), 
morphine and tramadol (pain relievers) (167). Other drugs paired with morphine or 
dexamethasone within this sub-network could be good starting points for further 
experimental validation for novel drug combinations. 
 
Among these 1508 predicted safe DDCs, 31 pairs contain at least one clinical trial 
evidence according to clinicaltrial.gov as pairs, including 6 pairs in phase I, 7 in phase II, 
12 in phase III, and 4 in phase IV. In contrast, for the 615 drug pairs with probability less 
than 0.01, only 11 are supported by at least 10 publications of clinical trial types in 
PubMed and with a much spare network (Figure 7-7D) compared to Figure 7-7A (p-value 
of 4.19×10
-7
 of chi-square Test).
 
When searching them against clinicaltrial.gov, only 2 of 
them have clinical trial records. 
 
Besides the results presented above with side effects integrated from both sources, we 
also checked the prediction performance by using side effects only from drug label (i.e. 
SIDER) or OFFSIDES with various machine learning models. If using drug label alone, 
the classification performance is as follows: AUC of 0.69 for Logistic Regression model; 
AUC of 0.68 for Naive Bayes model and AUC of 0.54 for decision tree model; If using 
OFFSIDES alone, the classification performance is as follows: AUC of 0.77 for Logistic 
Regression model; AUC of 0.71 for Naive Bayes model and AUC of 0.57 for decision 
tree model. The most predictive model was the one that included information from both 
OFFSIDES and SIDER, followed by OFFSIDES alone, then SIDER alone, which is 
consistent with previous findings (157).  
iii. Development of the rule-based model for DDC prediction  
Upon proving that the SEs could be used to predict DDCs, we next aimed at constructing 
a rule-based method to help the decision-making in a much easier and explainable way. 
We summarized this method as a two-step workflow (Figure 7-1): 
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Step 1: Prevent unsafe co-prescriptions based on only three SEs 
Here we aimed to find those side effects as markers to identify unsafe drug pairs. Of the 
239 approved DDCs in the database, 41 DDCs can be annotated with the side effect 
features. To get the random drug pairs, we generated all the possible pair-wise drug pairs 
from the 41 DDCs while excluding these 41 approved DDCs. We got 949 random drug 
pairs and 749 (Figure 7-8) can be annotated with side effects from TWOSIDES. We 
performed a Fisher’s Exact test for every side effect between these approved group and 
the random group, with 65 side effects identified as significant ( p-value <0.05).  
Next we tested the performance of using these 65 side effects to differentiate the 
approved DDCs from the random set. The positive set consists of 198 approved DDCs by 
ruling out those 41 DDCs in the training set from the 239 approved DDCs. To build the 
negative set, we randomized drug pairs in the positive set and 1255 unsafe drug pairs 
were identified by overlapping with TWOSIDES (Figure 7-8). The number of DDCs in 
 
Figure 7-8. Constructions of positive sets and negative sets from the 239 DDCs in the 
development of the FDA black list consisting of three side effects.  
Features were selected based on the positive and negative set on the left side of the figure 
while independent validation was done based on the positive and negative set on the right 
side. 
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positive set is approximately increased 5 times in the testing set compared to the training 
set. We built the features for each drug pair by checking whether zero, one or both of the 
drugs have any of the 65 side effect features. Similarly we applied decision tree analysis 
using WEKA (168). The AUC is 0.87 and the accuracy is 0.94. We checked the top 10 
features (Table 7-1) ranked by the information gain as statistical significance, and to have 
biological significance we chose three side effects out of these top 10 based on a wide-
spread of human organs or body systems of these side effects: pneumonia for lung or 
respiratory system, hemorrhage rectum for rectum or digestive system, and retinal 
bleeding for eye or visual system. With only these three side effects, the decision tree 
(Figure 7-9) achieved the AUC of 0.80 and accuracy of 0.91, supporting the superior 
performance of using this signature of three side effects to identify safe drug 
combinations. Other combinations of any three side effects from the list of 10 achieved 
lower performance. Based on this decision tree model (Figure 7-9), the candidate safe 
drug pairs should not have any of these side effects. We did a Fisher’s exact test between 
the approved DDCs and random drug pairs to tell whether overlapping of any of the three 
side effects between these two groups is significantly different and the p-value is 
2.66×10
-33
 with an odds ratio of 6.6 (Table 7-2). 
Table 7-1. Top 10 side effects features from the decision tree model 
Side effects 
Pneumonia 
Haemorrhage Rectum 
Neurodermatitis 
Retinal Bleeding 
Allergic Alveolitis 
Muscle Disorder 
Vitamin B 12 Deficiency 
Candida Infection 
Proctitis 
Infectious Mononucleosis 
 
 
Table 7-2. Confusion matrix of the relationships between having the three SEs in the 
black list and being the unsafe co-prescription 
 Share any of three SEs Share none of three  SEs 
Unsafe 1254 1037 
Approved combination 37 202 
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To rule out the possibility that the performance based on side effects as features is purely 
due to confounding factors like drug category, drug target, or disease indications of the 
drugs, we measured the drug combination classification performance with only the ATC 
(anatomical therapeutic chemical classification) drug category, drug targets, or disease 
indications. First we built a decision tree model on the same positive and negative sets 
with third level ATC code (153) as the features of pharmacology actions. It achieved an 
AUC of 0.62 with the top three features: G03C (i.e. Estrogens), N02A (i.e.Opioids), and 
C09A (i.e. Ace Inhibitors, Plain). Even with all the 100 ATC as features, the maximum 
AUC that can be achieved is 0.72, still less than the performance of the model based on 
the signature of only three side effects (i.e. AUC of 0.80). Similarly we built a decision 
tree model with drug targets as features and it achieved an AUC of 0.57 with the top three 
features: NR3C1, NR1I2, and rplD. Even with all the 296 target proteins as features, the 
AUC is 0.61, still less than the classification performance based on the signature of only 
three side effects. Finally we built a decision tree model with disease indication as 
features and it achieved an AUC of 0.54 with the top three features: Addison's disease, 
Eczema, and Prostate cancer. Even with all the 262 diseases as features, the AUC is 0.78, 
still less than the classification performance based on the signature of only three side 
effects. In sum, the decision tree model based on the signature of three side effects as 
features can achieve the highest performance to classify drug safety issues and it is not 
purely due to the co-founding factors like drug category, drug target, or disease 
indications. 
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Step 2: Making the DDC  
In Step one, drug pairs with good safety profile can be predicted. The further step is to 
identify which pairs should be put together to reach a certain efficacy level for a 
particular disease while sustaining a low SEs profile. For those drug pairs from Step1 that 
can be co-prescribed or made into a combination, we only considered those pairs with 
shared disease indications (Figure 7-1).  
 
We got 977 drug pairs along with at least one shared disease indication for each pair. We 
used literature co-occurrence as a statistical surrogate for the existence of relationships 
between the two drugs. 570 pairs (58%) have been supported by at least one publication 
of clinical trial types when searching both drug name in PubMed while 769 (79%) pairs 
 
Figure 7-9. The decision tree model to decide the drug pair safety. 
0, 1, and 2 indicates the number of drugs in the drug pair with such side effect. Pie charts 
indicate the percentage of correctly classified (green) and in-correctly classified (red) 
instances at each leaf. Safe represents the approved drug combinations while unsafe 
represents drug pairs from negative set.  
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have been supported by at least one PubMed publication of any type. 144 pairs (15%) 
have been supported by at least one clinical trial from clinicaltrial.gov. For the top 20 
predictions, we manually checked the clinicaltrial.gov and found 14 predictions with on-
going clinical trials are indeed the combinations. The studied conditions in all of the trials 
agree with our suggested disease indications. Table 7-3 shows the top drug pairs 
proposed by ‘Two Step Rule’. 
 
Table 7-3. Top drug pairs proposed by ‘Two Step Rule’.  
The Status column includes Approved, indicating that predicted pair has already been 
approved by FDA, and Predicted, meaning not approved yet; Indication column lists all 
the disease(s) shared by both components. CT column and the PM column list the 
number of items in clinicaltrials.gov or PubMed clinical literatures that mention the drug 
combination. 
Component_A Component_B Status Indication CT PM 
Dexamethasone Prednisolone Predicted Asthma 
Arthritis, rheumatoid 
28 255 
Dexamethasone Hydrocortisone Predicted Adrenal insufficiency, primary, 
congenital 
24 473 
Formoterol Fluticasone Predicted Asthma 16 55 
Abacavir Zidovudine Predicted Infection, HIV/AIDS 9 137 
Lamivudine Emtricitabine Predicted Infection, hepatitis-B virus 
Infection, HIV/AIDS 
8 77 
Bimatoprost Latanoprost Predicted Glaucoma 8 70 
Morphine Buprenorphine Predicted Pain, general 
Pain, post-operative 
Pain, musculoskeletal, unspecified 
4 215 
Pravastatin Atorvastatin Predicted Hypercholesterolaemia 4 176 
Dorzolamide Latanoprost Predicted Glaucoma 4 80 
Naltrexone Buprenorphine Predicted Addiction, narcotic/opiate 4 29 
Lisinopril Enalapril Predicted Hypertension, unspecified 
Heart failure 
3 153 
Formoterol Budesonide Approved Asthma 
Chronic obstructive pulmonary disease 
Bronchitis, chronic 
40 190 
Carbidopa Levodopa Approved Parkinson's disease 35 407 
Lamivudine Zidovudine Approved Infection, HIV/AIDS 28 587 
Timolol Dorzolamide Approved Glaucoma 21 161 
Levonorgestrel Estradiol Approved Hormone replacement therapy 19 487 
Lamivudine Abacavir Approved Infection, HIV/AIDS 16 195 
Ethinyl 
Estradiol 
Levonorgestrel Approved Hormone replacement therapy 
Contraceptive, female 
12 371 
Tamsulosin Dutasteride Approved Benign prostatic hyperplasia 6 17 
Benazepril Amlodipine Approved Hypertension, unspecified 5 51 
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For those predicted but not approved DDCs shown at the top of Table 7-3, all of them 
have been co-cited by at least ten clinical type literatures and three clinical trials. We also 
validated these co-prescriptions in FAERS, which contains millions of reports which 
record the drugs taken by individual patient and their adverse events. We performed a 
Fisher’s Exact test to identify whether two drugs are significantly recorded together at the 
same reports. I found that the majority of the novel predicted pairs are more likely to be 
co-reported or co-prescribed than by chance in FAERS (Table 7-4). All the above 
validations indicate great promise for further investigations of those novel drug 
combinations.  Table 7-5 also listed the top 10 drug pairs proposed by ‘Two Step Rule’ 
but are not in any clinical trials yet, which could be the candidates for developing novel 
fix-dose combinations. 
 
Table 7-4. Confusion matrix of co-prescription between the five predicted pairs.  
TP stands for the number of reports co-mentioned the two drugs; FP/FN stands for the 
number of reports only mentioned one of them; TN stands for the number of reports 
mentioned neither of them. 
Drug A Drug B TP FP FN TN p-value 
Abacavir Zidovudine 374 1143 4208 2220659 0 
Bimatoprost Latanoprost 2 117 804 2225461 2.21E-12 
Dexamethasone Hydrocortisone 113 15529 3244 2207498 1.67E-75 
Dexamethasone Prednisolone 343 15299 26338 2184404 2.86E-30 
Dorzolamide Latanoprost 22 80 784 2225498 0 
Formoterol Fluticasone 1 99 298 2225986 2.68E-05 
Lamivudine Emtricitabine 119 6621 692 2218952 0 
Lisinopril Enalapril 6 25933 1889 2198556 8.49E-04 
Morphine Buprenorphine 15 7754 475 2218140 1.13E-22 
Naltrexone Buprenorphine 0 81 490 2225813 1 
Pravastatin Atorvastatin 24 4434 2650 2219276 4.01E-15 
 
Table 7-5. Top 10 novel drug pairs without any clinical trials reported. 
Pair 
# 
Component_A Component_B Indication CT 
1 Ethinyl Estradiol Estrogen Hormone Replacement Therapy 0 
2 Morphine Marcaine Pain, Post-Operative 
Pain, General 
0 
3 Lovastatin Atorvastatin Hyperlipidaemia 
Alzheimer's Disease 
Hypercholesterolaemia 
0 
4 Captopril Enalapril Maleate Hypertension, Unspecified 
Heart Failure 
0 
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5 Lovastatin Pravastatin Hypercholesterolaemia 0 
6 Budesonide Beclometasone Asthma 0 
7 Abacavir Sulfate Zidovudine Infection, HIV/Aids 0 
8 Erythromycin Clindamycin Acne 0 
9 Fluticasone 
Propionate 
Beclometasone Asthma 
Rhinitis, Allergic, Seasonal 
0 
10 Norethisterone Medroxyprogesterone Contraceptive, Female 0 
 
iv. Case studies 
Here we looked into the proposed DDCs in Table 7-3. 
Dexamethasone/Prednisolone or Dexamethasone/Hydrocortisone (DDC#1 and #2) 
Prolonged use of glucocorticoid may impose variety of side effects and impact healthy 
anabolic processes. Elaboration of glucocorticoid drug combination, particularly with 
selectively acting glucocorticoid drugs or at reduced dose, could potentially help boost 
the therapeutic efficacy and prevent unwanted side effects or withdraw effects. This 
strategy has been explored and shown promises in multiple studies For examples, 
combination of prednisolone and low dosed dexamethasone is shown to exhibit greater 
anti-leukemic activity and lower drug resistance than equi-active dose of prednisolone 
alone (169) and the combination therapy using dexamethasone and prednisone has been 
shown to be more efficacious in patients with idiopathic sudden sensorineural hearing 
loss than individual glucocorticoid (170). As the above drugs are widely prescribed, there 
is also a great chance of being co-prescribed and, such as the two predicted combinations 
(i.e. glucocorticoids with different efficacy and potency) from our analysis could warrant 
further clinical testing in their overlapping indications such as asthma and rheumatoid 
arthritis.  
 
Abacavir/Zidovudine or Lamivudine/Emtricitabine (DDC #4 and #5) 
Combination therapy has been a key therapeutic option in the management of HIV/AIDS. 
For example, Abacavir and Lamivudine, a top ranked DDC predicted in this study, is one 
of the FDA approved drug combination. Additionally, our analysis identified several 
novel combinations that are not yet approved by FDA, for example, Abacavir in 
combination with Zidovudine, or Lamivudine in combination with Emtricitabine. Like 
other single antiviral agents, these drugs (Lamivudine, Emtricitabine, Abacavir), when 
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used on its own, cannot completely suppress viral replication thus allows for drug 
resistant strains to emerge. The combination of these drugs, however, can potentially 
impose stronger and more sustained effect than using any single drug alone.  
 
Formoterol/Fluticasone (DDC#3) 
Formoterol, a long-acting beta-adrenoceptor agonist, exerts bronchodilatation effect and 
is used in the management of asthma and chronic obstructive pulmonary disease (COPD). 
It’s already been tested and used in combination with corticosteroids, such as budesonide, 
to treat or prevent asthma attack and/or respiratory tract inflammation. Fluticasone, 
another potent glucocorticoid, has been shown to have superior or similar efficacy in 
improving pulmonary functions in asthma patients (171, 172). The predicted 
Formoterol/Fluticasone combination could be adopted as a new and alternative option in 
the management of asthma or COPD along the same combination strategy of 
Formoterol/Budesonide which warrants further validation for its clinical efficacy or 
safety profile.  
 
Dorzolamide/Lantanoprost (DDC# 9) 
Both Dorzolamide and Lantanoprost are anti-glaucoma agents yet with very different 
MOAs - the former is a carbonic anhydrase inhibitor that exerts pharmacological function 
by decreasing the production of aqueous humour, yet the latter agent is a prostaglandin 
analogue that increases outflow of aqueous fluid. With such distinctive and 
hypothetically complement mechanisms, the drug combination of these two agents could 
potentially exert stronger efficacy in reducing intraocular pressure particularly in severe 
glaucoma patients.  
 
The above two case studies (i.e. Pair # 3, #9) are the combination of agents from different 
categories with distinct MOAs. They could have additional and/or greater 
pharmacological and clinical benefits with their efficacy synergy potential, pill burden 
reduction, and improved compliance in patient care.  
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7.4 Conclusions 
Evaluation of drug pair safety is a critical issue for co-prescription or making fix-dose 
combinations (173, 174). Methods have been developed to predict drug-drug interactions 
(DDIs) from text mining (175, 176), network modeling (177), high-throughput screening 
(149), or computational data integration (153). Our approach exploring the possibility of 
predicting new drug pairs by representing drug combinations with their clinical side 
effects. It is based on the hypothesis that the drugs that can be put together usually do not 
have overlapping serious adverse drug reactions. The key advantage of using clinical side 
effect information lies in that it is direct observations from human subjects with fewer 
translational issues compared with data from in vitro or animal studies. The “signature” 
set of three side effects identified from our analysis provides a practical guideline to help 
rule out unsafe co-prescriptions. 
 
Using the integrated side effect data sources, we examined the effects of different 
machine learning methods on the prediction performance. For the prediction performance 
evaluation of 198 independent drug combinations with the features of the three side 
effects, decision tree model gives an AUC of 0.80, Naive Bayes with an AUC of 0.84 and 
Logistic Regression with an AUC of 0.84.  The robust performance across different 
machine learning methods confirms that our conclusion is not biased towards a particular 
method. We chose the decision tree model with the aim for easy clinical implementation 
despite that it doesn’t give the highest AUC. 
 
One limitation of side effect based on approaches to study DDCs or DDIs is that no good 
resource except for TWOSIDES is currently available to capture side effects of drug 
pairs. In our work of deriving the three side effects as a FDA blacklist based on 65 
signature side effects from TWOSIDES, we relied on the assumption that if we don’t 
want the drug combination to have any of the three side effects, we require that neither of 
the drug components  have such side effect. It is possible that even drug component itself 
doesn’t have such side effect, the combination may have it due to the potential drug 
interaction. This may undermine our classification performance. Nevertheless, our results 
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demonstrate that safe drug pairs usually do not have overlap in these three serious 
adverse drug reactions. 
 
The prediction performance of the three side effects is unlikely to be due to the bias in 
drug combinations’ disease profiles. The 41 drug combinations, where the signature of 
the three side effects was derived from, covered 24 diseases. We used an independent 
dataset of 198 drug combinations to measure their prediction performance. For this 
independent dataset, additional 68 diseases were covered. In other words, the disease 
profiles for these two datasets are different and this minimizes the bias during the 
prediction. On the other hand we need to be cautious to extrapolate the prediction model 
to apply to those drugs or diseases never shown up in our dataset since the scope of the 
prediction performance may be limited to these 245 drugs and 92 diseases.   
 
As discovered in the previous study (152), some side effects are associated with the 
indications of the drugs. For example, Actoplus Met is a fix-dose combination of 
metformin hydrochloride and pioglitazone hydrochloride. The two drug components 
share SEs of Anaemia; similarly, for another diabetes drug Duetact, a combination of 
Glimepiride and Pioglitazone Hydrochloride, these two drug components also share the 
SE of Anaemia. We hypothesize that for those side effects shared by approved drug 
combinations, they may be essential for the therapeutic effect of the drugs and they are 
usually not severe SEs. For example, the pharmacological effect anaemia is associated 
with reduced insulin consumption, which may alleviate the reliance on insulin of certain 
insulin resistant diabetes patients.   
 
Dosing is another factor that has to be considered when co-prescribing drugs in the 
clinical practice. Here we propose a simplified model for discussion. When the 
concentration becomes lower, e.g., halving the dose for each component when making 
the DDC, the dose-related toxicity of this combination may thus be halved. However, 
since we require that drug components should have the same indication in our model, the 
efficacy may theoretically remain the same or even better due to the synergistic effect of 
the combination. We understand the real situation in the dosing issue is much more 
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complex, however. This is only an ideal model that inspires further discussion and deeper 
understand of the making of DDCs. Further clinical trials are needed to validate its 
efficacy on a particular dosing. Besides by choosing the right drug pairs, e.g., one 
expensive drug along with a cheaper one, with reduced doses, it may also bring 
economics of combining the drugs.   
 
We suggest that our predictions may be beneficial in three areas: (i) improving the safety 
profiles of drug co-prescriptions in clinic; (ii) assessing potentially hazardous drug 
combinations in early stage of the fix-dose combination discovery in pharmaceutical 
industry; and (iii) potentially reducing pill burden or bringing economics of combining 
the drugs. While our predictions were validated in-silico, they should be further tested 
experimentally to establish their clinical implications.  
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Chapter 8. Conclusions 
8.1  Research summary and contributions 
In summary, the thesis presents a comprehensive framework of computational drug 
discovery, using system approaches. The thesis mainly consists of two parts: disease 
biomarker identification and disease treatment discoveries. 
 
I start by introducing the research in biomarker identification for human diseases in the 
post-genomic era with an emphasis in system biology approaches such as using the 
protein interaction networks. Diagnostic biomarker is expected to detect a given type of 
disease in an individual with both high sensitivity and specificity; predictive biomarker 
serves to predict drug response before treatment is started. Both are essential before we 
even start seeking any treatment for the patients. In Chapter 2, I studied how the coverage 
of the disease genes, the protein interaction quality, and gene ranking strategies can affect 
the identification of disease genes; In Chapter 3, I addressed the challenge of constructing 
a central database to collect the system level data such as protein interaction, pathway, etc. 
for the biomarker discovery at the system biology level. In Chapter 4, I built case studies 
for biomarker identification for Diabetes by using the conclusions from Chapter 2 and 3.  
The second part of the thesis mainly addresses how to find treatments after disease 
identification.  I specifically focus on computational drug repositioning due to its low 
cost, few translational issues and other benefits. In Chapter 5, I described how to 
implement literature mining approaches to build the disease-protein-drug connectivity 
map and demonstrated its superior performances compared to other existing applications. 
In Chapter 6, I presented a valuable drug-protein directionality database which filled the 
research gap of lacking alternatives for the experimental CMAP in computational drug 
discovery field. The correlation based ranking algorithm was also extended to include the 
underlying topology among proteins. Chapter 5 and 6 conclude the thesis work of drug 
repositioning in the genomic level. In Chapter 7, I demonstrated how to study drug 
repositioning beyond genomic level and from one dimension to two dimensions. In 
specific I explored how to propose drug combination with clinical side effects as 
prediction features.    
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8.2 Future research directions 
The computational workflow for drug discovery in genomics level can be generally 
represented as in Figure 8-1. The future research directions can be extended from each 
step, especially step 1, 3 and 4. 
 
i. Research in identifying reliable disease biomarker 
How to get a consistent panel of biomarker for each disease regardless of platforms and 
other confounding factors is a central topic in biomarker discovery (Step 1 in Figure 8-1). 
The emerging of NGS techniques, specially the RNA-Seq, may be good alternatives for 
genomic profiling compared to microarray techniques.  It has been shown to be more 
reliable and accurate measurement of gene expression level with the NGS techniques. 
The methodology of biomarker discovery in this thesis can be readily applied to the 
expression level from RNA-Seq experiments.  
 
 
Figure 8-1.The general workflow of computational drug discovery. 
 
1) Reliable diseases 
genes with 
directionality 
2) Reliable drug 
genes relationship 
with directionality 
3) Disease models that links drug to effected proteins 
4) Ranking algorithms that take directionality and disease 
models as inputs  
5) Proposed drugs for each disease 
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Future investigators should ideally build a probabilistic-based catalog of biomarkers 
(Step 1 in Figure 8-1) for each disease condition just as how DMAP are built for 
recording the relationships between drugs and proteins. This central database will not rely 
on single detection technology and should serves as a knowledge base for any disease 
biomarker study. Once we have a central database for disease and protein relationship, 
we could combine it with DMAP with the framework presented in the thesis to propose 
more reliable treatments. 
ii. Research in disease model discovery 
While the conventional “One disease, One gene, and One drug” paradigm works 
effectively for simple genetic disorders, it fails to produce effective drugs for complex 
diseases such as cancer. In complex diseases, many genes may be contributing to the 
disease’s phenotype. Thus building a disease model (Step 3 in Figure 8-1) to explain the 
underlying disease mechanism is essential for developing effective disease treatments. In 
the thesis, I focused on breast cancer disease model for proof of concept. More disease 
models should be built and tested to check the robustness of the computational 
framework. The cost of utilizing the pathway information is that one has to put more 
effort in data collection and pathway construction. Ultimately a database containing 
disease models for major diseases is desirable. Such a disease-oriented database will 
provide much better resolution than traditional protein interaction databases for 
computational drug discovery. 
iii. Research in disease ranking algorithms 
In the thesis, PETS algorithm was proposed to utilize the underlying topology of the 
disease model to rank the potential treatments. It has shown a superior performance in 
breast cancer study. Future investigators need test this algorithm in more disease models.  
Ideally one could provide an integrative tool for wet-lab scientists to use for drug 
discovery by integrating the disease biomarker catalog, DMAP, and disease model 
database. 
iv. Beyond genomics 
Matching the disease expression profile with the drug perturbation expression profile is a 
mainstream approach in the computational drug discovery nowadays. Despite its 
popularity, few researchers or companies have yet proposed any drugs for FDA approval 
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based on this approach. The major challenge here is how to translate the discovery in 
molecular level to phenotypic level. We have at least two ways to address the 
translational issues. 
 
One way is to build the prediction model with clinical features such as drug side effects. 
Since side effects are directly observed from human, the translation issues will be less of 
a concern. In Chapter 7, I have shown how to predict drug combination using side effects 
as features. Future investigators need continue to pay more attention to side effects and 
other measurements in clinical trials studies and utilize them to build computational 
models. 
 
Another way is to utilize the Electronic medical record (EMR), a system that contains all 
of a patient’s medical history from one practice. It contains detailed information about 
patients’ phenotypic responses for various drugs. As the first step moving towards this 
direction, I built a statistical model to use FAERS to identify what drug combination is 
more inclined to be prescribed by doctors in Chapter 7.  Utilizing the EMR can not only 
serve as the validation purpose of any proposed treatments, but also help uncover any off-
label use by the clinicians. Models based on those data can leverage the knowledge 
accumulated by clinician’s daily practice and will be appreciated. 
 
With the continued research and development in computational drug discovery, and with 
incoming of the big data in bioinformatics, the drug discovery, especially drug 
repositioning, tailored to the individual patient will be realized. 
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